
==== Front
NPJ Vaccines
NPJ Vaccines
NPJ Vaccines
2059-0105
Nature Publishing Group UK London

953
10.1038/s41541-024-00953-6
Review Article
Type 5 secretion system antigens as vaccines against Gram-negative bacterial infections
http://orcid.org/0000-0002-2144-6496
Da Costa Rochelle M. 1
Rooke Jessica L. 1
http://orcid.org/0000-0001-7766-5404
Wells Timothy J. 2
Cunningham Adam F. 3
Henderson Ian R. i.henderson@uq.edu.au

1
1 https://ror.org/00rqy9422 grid.1003.2 0000 0000 9320 7537 Institute for Molecular Bioscience, The University of Queensland, Brisbane, QLD Australia
2 https://ror.org/00rqy9422 grid.1003.2 0000 0000 9320 7537 Frazer Institute, The University of Queensland, Brisbane, QLD Australia
3 https://ror.org/03angcq70 grid.6572.6 0000 0004 1936 7486 Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, United Kingdom
1 9 2024
1 9 2024
2024
9 15913 2 2024
14 8 2024
© The Author(s) 2024
2024
https://creativecommons.org/licenses/by-nc-nd/4.0/ Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc-nd/4.0/.
Infections caused by Gram-negative bacteria are leading causes of mortality worldwide. Due to the rise in antibiotic resistant strains, there is a desperate need for alternative strategies to control infections caused by these organisms. One such approach is the prevention of infection through vaccination. While live attenuated and heat-killed bacterial vaccines are effective, they can lead to adverse reactions. Newer vaccine technologies focus on utilizing polysaccharide or protein subunits for safer and more targeted vaccination approaches. One promising avenue in this regard is the use of proteins released by the Type 5 secretion system (T5SS). This system is the most prevalent secretion system in Gram-negative bacteria. These proteins are compelling vaccine candidates due to their demonstrated protective role in current licensed vaccines. Notably, Pertactin, FHA, and NadA are integral components of licensed vaccines designed to prevent infections caused by Bordetella pertussis or Neisseria meningitidis. In this review, we delve into the significance of incorporating T5SS proteins into licensed vaccines, their contributions to virulence, conserved structural motifs, and the protective immune responses elicited by these proteins.

Subject terms

Protein vaccines
Protein vaccines
issue-copyright-statement© Springer Nature Limited 2024
==== Body
pmcIntroduction

Infectious diseases are a leading cause of mortality worldwide. However, the number of deaths are amplified by antimicrobial resistance (AMR), which results from the extensive and inappropriate use of antibiotics used to combat infections1. A recent study revealed AMR associated deaths reached 4.95 million in 2019, making it a global health threat2. Moreover, a comprehensive evaluation of peer-reviewed studies and healthcare data predicts a potentially dire scenario: by 2050, up to 10 million lives annually might succumb to AMR-related causes3. With the incidence of deaths due to bacterial infections increasing annually, the need for alternative approaches to treat bacterial infections is increasing4. A pivotal strategy in averting AMR infections lies in vaccination. Vaccination is a prophylactic measure to fight infectious diseases, thus reducing the need for antibiotics and the long-term consequences of infection. Vaccines induce protection against a pathogen by eliciting an immune response that decreases the severity of the diseases5. Remarkably, vaccines rank among the most successful medical interventions in human history; for instance, the smallpox vaccine alone elevated life expectancy from 58.5 to 70 years4. According to the WHO, due to increased vaccine availability and compliance across the globe, since 2017 there has been a 90% decrease of vaccine-preventable infectious diseases such as diphtheria, measles, tetanus, pertussis, polio, and rubella6.

Despite the success of vaccines in preventing bacterial infections, vaccines are still lacking against most major bacterial diseases. Numerous challenges impede vaccine success, including the prolonged duration for vaccine development and licensure, limited knowledge about immunogenic antigens, and an incomplete understanding of the immune responses linked to protection7. Furthermore, obstacles like inadequate health infrastructure, inadequate vaccine cold-chain management in low- and middle-income countries restrict vaccine accessibility in these regions. Additionally, the intricate diversity and complexity of bacterial pathogens further complicates the development of new vaccines8. To address these challenges, innovative technologies are needed to overcome the limitations of current vaccines and enhanced comprehension of protective immune responses against infections would propel the development of new vaccines against other emerging bacterial pathogens9. This review explores the potential use of T5SS proteins as vaccine candidates and examines the outcomes of licensed bacterial vaccines employing these proteins.

Antibodies as mediators of protection

Vaccines function primarily by eliciting immune protection through the production of antibodies and the promotion of humoral immunity. This humoral immune response is initiated when antigens interact with antigen presenting cells (APCs) like B-cells. T-helper cells or CD4+ T cells are required for the activation of B-cells and the production of antibodies. CD4 + T cells are further divided into Th (T helper) 1, Th2, Th9, Th17, Th22, Treg (regulatory T cells) and Tfh (follicular helper T cells)10,11. Th1 cells produce interferon-gamma (IFN-γ), interleukin (IL-2) and tumour necrosis factor (TNF), promote cell-mediated immunity and control infections by intracellular pathogens. Th2 cells produce IL-4, IL-5, IL-10 and IL-13, and promote antibody mediated immunity. Studies have shown that a balanced Th1/Th2 response is required to optimise the protective effect of vaccines, such as the Group A Streptococcus vaccine12,13. Th17 produce IL-17 which plays an important role in protective immunity against pathogens by recruitment of neutrophils to the site of infection. Tfh cells help B-cells to produce antibodies and are particularly important with respect to vaccination as they play a role in the development of a protective antibody response against pathogens14. Almost all vaccines, including those for smallpox, diphtheria, tetanus, pertussis, polio, and Haemophilus influenzae type b (Hib), operate by triggering the production of antibodies. In these diseases, antibody titres generated post immunisation have been shown to correlate with protection7.

Antibodies consist of two light and two heavy chains bound together by disulphide bonds (Fig. 1). Within the antibody structure, the fragment of antigen binding (Fab) portion engages in antigen recognition, while the fraction crystallisable (Fc) portion plays a pivotal role in interactions with host cells, significantly influencing antibody function15. Based on the heavy chain constant region the antibodies are classified into various isotypes that differ in function: IgM, IgG, IgA, IgD and IgE. IgD is an enigmatic antibody whose function remains unknown and IgE is involved in allergic reactions. IgD and IgE are not considered further here. IgM is the first antibody produced during an immune response following infection or immunisation and is found in the blood. IgM is more efficient at fixing complement than IgG. This is attributed to the pentameric structure of IgM; a single pentameric IgM molecule has five Fc regions as opposed to a single Fc region in IgG, thereby making it more potent than IgG at binding complement components16. Research using IgM knockout models has underscored the crucial role of IgM in reducing susceptibility to typhoid infection17. Moreover, immunisation of mice with Salmonella enterica Typhimurium porin OmpD (Outer membrane protein D), revealed that IgM was required for vaccine-mediated protection18. IgG appears a little later and is the most abundant isotype in human serum. IgG is divided into four subclasses in humans (IgG1, IgG2, IgG3 and IgG4), and in mice (IgG1, IgG2a, IgG2b and IgG3). The subclasses differ in the length of the hinge region. Studies have shown that human IgG3 and IgG1, and mouse IgG2a, IgG2b and IgG3 are more efficient at fixing complement. This reason is attributed to the length and flexibility of the hinge region, which results in less steric hindrance for complement binding when compared to the other IgG subclasses19,20. Evidence from multiple studies show that the human IgG3 followed by IgG1 is crucial for mediating phagocytosis of the pathogen21. Since IgG1 accounts for 70% of the total IgG and is the most abundant subtype of IgG, deficiency of IgG1 is associated with a decline in total IgG concentration22. Capsular polysaccharide antigens predominantly induce IgG2 antibodies and studies have shown that deficiency of this antibody subtype results in increased susceptibility to bacterial infections19,23. Protein conjugate vaccines such as Pneumococcus type-6B tetanus toxoid vaccine induce IgG1 and IgG3 antibodies24. IgG4 is the least abundant immunoglobulin subtype and, like IgE is associated with allergic reactions25. IgA is the most abundant antibody and exists in monomeric form in serum and dimeric form in mucosal secretions. Evidence shows that patients with IgA and IgG deficiency are more susceptible to severe respiratory infections26. Thus, the induction of specific antibody isotypes and subclasses holds paramount importance in vaccine-mediated protection. However, the effectiveness of these antibodies depends on their functionality and quantity27.Fig. 1 Immunoglobulin (Ig) classes.

In humans, Ig classes are made up of two light chains (purple) and two heavy chains (orange) that are joined by disulphide bonds. The Fab (Fragment of antigen binding) region is involved in antigen binding. The variable region is made up of heavy and light chains VH and VL respectively and are involved in antigen binding. The constant region includes CH1, CH2 and CH3. The Fc portion of the Ig is involved in interaction with cells and effector molecules. a IgM exists as a pentamer or hexamer joined by disulphide bonds and a Joining (J) chain. b IgG exists as 4 subclasses in humans: IgG1, IgG2, IgG3 and IgG4 which differ in hinge length. c IgA exist as two subclasses IgA1 and IgA2. The two subclasses exist in monomeric from in serum and dimeric form in mucosal secretions. The figure was created using BioRender.com.

Antibodies play various roles in defending against pathogens, including neutralization, phagocytosis, complement-mediated killing, activation of mast cells and eosinophils, and antibody-dependent cellular toxicity (ADCC) (see Fig. 2). For instance, to safeguard against infection, the meningococcal vaccine (Bexsero) induces antibodies that function by mediating complement-dependent killing of Neisseria meningitidis28. The importance of functional antibodies is illustrated by numerous studies showing increased susceptibility to bacterial infections in individuals with primary immunodeficiencies. Furthermore, several studies have demonstrated that patients with myeloma and chronic renal failure have a higher risk of developing Hib disease when compared to healthy individuals. As circulating antibodies typically protect against invasive Hib disease by activating complement and phagocytosis, this phenomenon was attributed to a lack of functional antibodies29. Hence, comprehending the functionality of specific antibodies and their relationship with protection against infections can offer valuable insights into vaccine effectiveness and design. Specifically, antibodies targeting outer membrane proteins play a pivotal role in Salmonella eradication, emphasizing the significance of complement-mediated killing in controlling Salmonella infections. However, the O-Antigen (O-Ag) of the lipopolysaccharide (LPS) can hinder antibody access to the protein antigens30. Furthermore, excess antibodies to LPS can inhibit complement-mediated killing of Salmonella31, Uropathogenic Escherichia coli (UPEC) and Pseudomonas aeruginosa, and is correlated with poor outcomes27,32. The development of an LPS-based conjugate vaccine, Aerugen against P. aeruginosa was suspended during a randomized phase III trial due to poor outcomes. The failure of this vaccine is likely due to excess IgG2 antibodies to the O-Ag that blocks complement mediated killing of the pathogen27,33. Hence, understanding antibody function, the accessibility of antibodies to the antigen, antibody titres, and the target site are important for vaccine design.Fig. 2 Mechanism of action of antibodies.

The mechanism of antibody mediated protection includes a Neutralisation- Neutralising antibodies bind to a bacterial toxin and prevent it from binding to the toxin receptors on the host. b Opsonisation and phagocytosis- Antibodies bind to the antigen on the surface of the bacterial cell and are recognised by the Fc receptor on macrophages resulting in phagocytosis of the pathogen. c Complement mediated killing- Binding of complement (C1 complex) to the antibody activates the complement pathway and leads to the formation of the membrane attack complex (MAC) resulting in lysis of the bacterial cell. d Antibody dependent cellular toxicity (ADCC)- the Fc receptor on the effector cell such as Natural killer (NK) cell recognises and kills the antibody coated target cell. e Mast cell activation- IgE antibodies are involved in allergic reactions and bind to the receptors of mast cells resulting in activation and degranulation of mast cells. The figure was created using BioRender.com.

Licensed bacterial vaccines

Vaccines can be classified into live attenuated vaccines and non-live vaccines in which the antigenic component of the vaccine can be composed of whole cells, outer membrane vesicles (OMVs), polysaccharides, and/or proteins. A list of the currently licensed bacterial vaccines is presented in Table 1.Table 1 List of bacterial vaccines licensed for use in humans

Vaccine type	Strain	Diseases	Licensed vaccine/comments	References	
Whole cell vaccine	Bordetella pertussis	Whooping cough	DTwP	149	
Clostridium tetani	Tetanus	DTwP	149	
Corynebacterium diphtheriae	Diphtheria	DTwP	149	
Vibrio cholerae	Cholera	Dukoral, Shanchol, Euvichol	150	
Yersinia pestis	Plague	No FDA approved vaccine	151	
Coxiella Burnetti	Q fever	Q-vax	152	
Salmonella Typhi	Typhoid	Discontinued	153	
Live attenuated	Mycobacterium bovis	Tuberculosis	BCG	154	
Salmonella Typhi	Typhoid	Ty21a	155	
Francisella tularensis	Tularaemia	LVS	156	
Bacillus anthracis	Anthrax	Ava BioThrax	157	
Vibrio cholerae	Cholera	Vaxchora	158	
Polysaccharide	Neisseria meningitidis	Meningitis	MenACWY	159	
Streptococcus pneumoniae	Pneumonia	PPV23	160	
Haemophilus influenzae	Meningitis	Hib conjugate vaccine	161	
Salmonella Typhi	Typhoid	Vi capsular polysaccharide	162	
Toxoid	Clostridium tetani	Tetanus	DTaP	163	
Corynebacterium diphtheriae	Diphtheria	DTaP	163	
Bordetella pertussis	Whooping cough	DTaP	163	
Protein	Neisseria meningitidis	Meningitis	Bexsero/4CMenB, MenZB	164	
Bordetella pertussis	Whooping cough	aP vaccine	165	
Borrelia burgdoferi	Lyme diseases	VLA15	166	
OMV	Neisseria meningitidis	Meningitis	Bexsero/4CMenB, MenZB, MenBVac, VA-MENGOC-BC	164	

Live-attenuated vaccines

Live-attenuated bacterial vaccines, including the BCG, Typhoid (Ty21a) and Vibrio cholerae (CVD 103-HgR) vaccines, have been extensively used over years34–36. Live attenuated vaccines mimic a natural infection and deliver multiple antigens that have the potential to mediate both a humoral and cell-mediated immune response. The main disadvantages of this category of vaccines are the potential to cause infection in immunocompromised individuals, the risk of releasing live recombinant bacteria into the environment, reversion of the mutants to the wild type phenotype, and short-term efficacy37. For example, Ty21 is a live attenuated vaccine which protects against Salmonella Typhi infections38,39, however, the vaccine is limited by poor immunogenicity in children, is not suitable for immunocompromised individuals, and is only protective against S. Typhi, and no other Salmonella infections40.

Inactivated whole cell vaccines

Whole cell vaccines are obtained by inactivation of bacteria by heat, chemicals, or irradiation. Immunisation with whole cell vaccines induces the humoral immune response and the activation of CD4+ T cells that together mediate protection. Currently, licensed inactivated whole cell vaccines include those protecting against V. cholerae, Coxiella burnetii and Bordetella pertussis. The whole cell pertussis vaccine (wPV) contributes to bacterial clearance by inducing the production of opsonising antibodies and activation of the complement system41. The drawbacks associated with the wPV are high incidences of swelling, induration and fever following immunisation42. Unsubstantiated claims of a causal link to neurological disorders diminished parental confidence in this vaccine and as a result most industrialised countries have now switched to the acellular pertussis vaccine (aP) described later; however, wPV is still used in low- and middle-income countries and has a better efficacy than aP43,44.

Polysaccharide-based vaccines

The bacterial capsular polysaccharide (CPS) is attached to the outer membrane (OM) and is an important virulence factor preventing phagocytosis and complement-mediated killing45,46. Polysaccharide-based vaccines have been licensed against N. meningitidis, Haemophilus influenzae, Streptococcus pneumoniae and S. Typhi. Purified polysaccharides can overcome some of the safety concerns associated with live-attenuated and whole cell vaccines47. Immunisation with polysaccharide-based vaccines induces T-cell independent responses and anti-polysaccharide antibodies that protect against infection by mediating complement-dependent killing and opsonophagocytosis48. Limitations of polysaccharide-based vaccines include that polysaccharide antigens elicit poor antibody titres in immunocompromised individuals, immune responses are short-lived, and are not effective in children49. For example, the Vi vaccine has not been licensed in children due to its poor immunogenicity in this age group and does not protect against infections with nontyphoidal strains of S. enterica40. One way to address these constraints is by conjugating polysaccharides to a protein carrier, a strategy employed in the licensed typhoid conjugate vaccine and pneumococcal vaccines like Prevnar 13 and Pneumovax 23; these conjugate vaccines trigger long-lasting immune responses that are well-tolerated and significantly bolster protection50,51.

Outer membrane vesicle (OMV)-based vaccines

OMVs are naturally occurring nanoscale bi-layered membrane structures produced by vesiculation of the outer membrane and have a diameter of 20–250 nm52. They are composed of LPS, outer membrane proteins (OMPs) and phospholipids on the outside, and phospholipids and inner membrane proteins on the inside52. The lumen of the OMV contains periplasmic and cytoplasmic proteins, RNA, DNA and peptidoglycan53. OMVs possess pathogen associated molecular patterns (PAMPS) that are required for APC-mediated activation of T-cells. OMVs have emerged as an attractive vaccine platform which was first used to develop vaccines against N. meningitidis infections54. OMV vaccines were first used to address the meningococcal epidemics in Cuba (VA-MENGOC-BC)55, Brazil (VA-MENGOC-BC)56, Norway (MenBVac)57 and New Zealand (MeNZB)58. However, the immunogenicity of these vaccine largely depended on an immunodominant protein Porin A (PorA) that is highly variable across different strains. As a result, the protection offered by these vaccines was limited and was only effective against strains dominated by a single PorA59. To address this, the Bexsero vaccine was developed. It consists of three subunit proteins, identified by reverse vaccinology, combined with detergent extracted OMVs from the New Zealand strain NZ98/254, which contains PorA60. Studies have shown that the OMV vaccine platform can induce a long lasting humoral and cellular immune response. Immunisation with OMVs induce high levels of IgG antibodies, which correlate with complement-mediated killing and opsonophagocytic antibodies61,62.

Limitations to preparing OMVs by detergent extraction include LPS toxicity and the potential loss of protective antigens that are naturally associated with the OM. Lipid A is the endotoxic part of the LPS and is composed of 6 acyl chains. To reduce toxicity, genetic modification of the parent strain can be used to alter the structure of lipid A to a penta-acylated form63. Notably, genetically produced GMMA (generalised modules for membrane antigens) are OMVs generated through the deletion of genes such as tolR, msbB, and pagP. Deletion of tolR enhances OMV release from the outer membrane and deletion of msbB and pagP results in penta-acylated lipid A53. Studies have shown that penta-acylated lipid A had reduced endotoxicity64, thereby improving its use in vaccine studies. Currently, GMMA-based vaccines are in development against Shigella, Salmonella and Neisseria65–67. The OMV vaccine platform presents distinct advantages over alternative approaches. These vaccines are self-adjuvating, encompass numerous antigens from the outer membrane, maintain these antigens in their natural conformation, boost cost-effectiveness in manufacturing, and production can be readily replicated for various other Gram-negative bacteria68.

Protein-based vaccines

Protein-based vaccines are composed of one or more purified proteins obtained from an infectious agent. In some instances, these proteins are chemically rendered inactive. For instance, widely used vaccines for diphtheria and tetanus are produced by isolating toxins from bacterial growth medium and subsequently rendering them non-toxic using formaldehyde. In contrast, acellular protein-based vaccines designed to safeguard against infections caused by entire bacteria, like those targeting B. pertussis (aP) and N. meningitidis serogroup B (Bexsero), require multiple antigenic components. In the case of the aP and Bexsero vaccines, the antibodies induced by these vaccine components serve several crucial functions. They neutralize the function of the disease-causing agents, trigger complement-dependent killing mechanisms, and enhance opsonophagocytosis69. These protein antigens are typically outer membrane proteins or proteins transported to the bacterial cell surface through various secretion systems.

Protein secretion mechanisms in Gram-negative bacteria

Bacteria possess a diverse range of secretion systems that enable the transfer of proteins, DNA, and small molecules to the external environment. In the case of Gram-negative bacteria, eleven protein secretion pathways have been identified to date, including Type 1-Type 6, Type 8-Type 11 and the chaperone usher pathway70. These protein secretion systems operate through either a one-step or two-step translocation process to deliver proteins across the bacterial cell envelope. In one-step translocation, also known as Sec-independent systems, substrates are transported directly from the cytoplasm to the extracellular milieu or the interior of the host cell. Notable examples of this one-step translocation system are found in double-membrane-spanning secretion systems such as Type 1, Type 3, Type 4, and Type 6. Conversely, the Type 2, Type 5, Type 8 through Type 11, and the chaperone usher pathways employ a two-step translocation mechanism. For the latter systems, substrates are first translocated to the periplasm with the help of inner membrane-spanning transporters such as SecYEG translocon or Tat (twin-arginine translocation system)71–74. Subsequently, these substrates are transported to the OM or released into the extracellular space. In the case of the aP vaccine, its components encompass the Type 4 secreted pertussis toxin, two fimbrial antigens secreted via the chaperone usher pathway, and two Type 5 secreted proteins, Pertactin and Filamentous Haemagglutinin (FHA)75. Similarly, the Bexsero vaccine combines four distinct elements: the OMVs from the New Zealand strain NZ98/254 containing PorA, the cell surface-associated proteins factor H binding protein (fHbp) and neisserial heparin binding antigen (NHBA), and the Type 5 secreted protein NadA76. The effectiveness of the Type 5 proteins in the Bexsero and aP vaccines suggest similar proteins may form the basis of vaccines against other pathogens. The type of immune response and protection generated by the Type 5 proteins in the licensed pertussis and meningitis vaccines is discussed in the later sections.

Type 5 secretion system

Among the various secretion systems, the Type 5 secretion system (T5SS) is the most prevalent protein secretion system in Gram-negative bacteria and frequently plays a crucial role as virulence factors during infections71,77. T5SS proteins contribute to a wide array of functions, including adhesion, aggregation, biofilm formation, proteolysis, serum resistance, pathogenesis, and serve as significant virulence factors78. Proteins secreted via this mechanism generally exhibit a tripartite structure: an N-terminal signal sequence, a passenger, and a β-barrel translocator domain79. Initially, these proteins traverse the inner membrane (IM) through the SecYEG translocon. In the periplasmic space, signal peptidases cleave the signal sequence, and chaperones, such as Skp, SurA, and DegP, facilitate the transfer of the remainder of the protein across the periplasmic space to the BAM complex within the OM. The BAM complex plays a crucial role by inserting the translocator domain into the OM as a β-barrel and facilitating the passage of the passenger to the cell surface through the β-barrel’s pore80,81. Once at the cell surface, the passenger may either remain attached to the cell’s surface or be released into the extracellular space82.

Subclasses of the T5SS

Depending on the domain architecture, the T5SS can be divided into five subclasses: Type 5a-e71,77 (Fig. 3). Within the different classes of the T5SS proteins, the β-barrel domain is highly conserved but the functional passengers display much more heterogeneity indicative of evolutionary and immunological pressures77. Proteins that are members of the Type 5a secretion system (T5aSS) are also known as classical or monomeric autotransporters. Classical autotransporters are comprised of a signal sequence at the N-terminus, a passenger, and a 12-stranded β-barrel domain at the C-terminus. Examples of this pathway include IgA protease from N. meningitidis, the first member of this family to be described, Tsh from Escherichia coli, and Pertactin from B. pertussis81. The Type 5b secretion system (T5bSS) is also known as the two-partner secretion system. Type 5b proteins also have a passenger and β-barrel domain, but these are encoded on separate genes77,78,81. In addition, the β-barrel domain has a 16-stranded β-barrel instead of 12 and contains two polypeptide transport associated (POTRA) domains and bears homology to BamA, the central component of the BAM complex77. The passenger polypeptide is referred to as the TpsA protein and the translocator as TpsB. The best characterized member of this subfamily is Filamentous haemagglutinin (FHA) of B. pertussis. The Type 5c secretion system (T5cSS) is made up of trimeric autotransporter adhesins (TAAs). TAAs have all domains encoded on one gene, but the C terminal β-barrel domain is made of three polypeptide chains, each contributing four β strands to the 12-stranded β-barrel in the OM. As a result, the nascent polypeptide chains must trimerize to form a complete barrel to enable translocation of the passenger. While the best characterized trimeric autotransporter is YadA from enteropathogenic Yersinia enterocolitica, which is involved in adhesion to host cells, other examples include NadA, a component of the Bexsero vaccine against N. meningitidis77,83. The Type 5d secretion system (T5dSS) is also known as the fused two partner section; thus far these proteins are lipases that have patatin like domains77,81. Like the classical autotransporters, the T5dSS proteins are transcribed as a single polypeptide, but possess POTRA domains like the T5bSS. Examples of the T5dSS proteins include PlpD from P. aeruginosa and FplA from Fusobacterium nucleatum78. In contrast to the classical autotransporters, the order of the passenger and β domain are reversed in the Type 5e secretion system (T5eSS) such that the C-terminus of the protein is presented on the surface of the bacterial cell and the N-terminus encodes the β-barrel domain. Intimin from E. coli and Invasin from Y. enterocolitica are well characterized T5eSS proteins81.Fig. 3 Subclasses of the Type 5 secretion system.

Type 5 secreted proteins consist of a signal sequence, passenger, and translocator domain. Type 5 secretion is further divided into Types 5a–5e. Proteins that are members of the Type 5a secretion system (T5aSS) have a signal sequence at the N terminal, a passenger and β-barrel domain at the C terminal. An example of this subclass is Pertactin (retrieved from AlphaFold database, UniProt accession Q8RSU0). Type 5b is also known as two-partner secretion (TPS) where the passenger and the translocator domain are encoded for on two separate genes, which are translated into separate polypeptides. The TPS β-barrel domain has two POTRA domains. An example of this subclass is FHA with crystal structures for the N-terminal region of the passenger and translocator domain (retrieved from PDB 1RWR and 4QKY, respectively). The Type 5c secretion system (T5cSS) consists of proteins that assemble to form a trimer and are also known as trimeric autotransporter adhesins (TAAs). An example of this subclass is NadA with crystal structure for the N-terminal region of the passenger (retrieved from PDB 6EUN) and the translocator domain (residues 341–405) was generated using ColabFold194. The Type 5d protein is also known as fused two partner secretion, where the β-barrel domain also contains a POTRA domain. An example of this subclass is PlpD (retrieved from AlphaFold database, UniProt accession A0A0A8RFV7). A recent study by Hanson et al. has proposed that the passenger of PlpD is facing the periplasm195. Type 5e has the passenger at the C terminus and extends from the outer membrane of the cell. An example of this subclass is the crystal structures for Intimin (retrieved from PDB 1F02 and 6TQD for the passenger and 4E1S for the translocator domain). The figure was created using components from Alphafold, PDB and BioRender.com.

Licensed vaccines containing T5SS proteins

Numerous research studies have concentrated on harnessing T5SS proteins as viable vaccine antigens. These proteins exhibit several characteristics that render them ideal candidates for vaccines, including their proven role in pathogenesis and their localisation of the functional passenger domain on the bacterial cell surface, making them targets for immune responses mediated by antibodies. As noted above, two of the antigens of the aP vaccine belong to the type 5a (Pertactin) and type 5b (FHA) subclass of T5SS proteins84,85. The Bexsero vaccine is a recombinant meningococcal vaccine containing NadA, a trimeric autotransporter (type 5c)83. The following section delves into the outcomes of licensed vaccines based on T5SS proteins, providing insight into why these proteins are included in licensed vaccines, as well as their roles in infection and their immunogenic properties.

Bordetella pertussis vaccines

Pertussis, also known as whooping cough, is a severe acute respiratory disease caused by the Gram-negative bacterial pathogen B. pertussis86. Whooping cough was a leading cause of death worldwide until the introduction of vaccines. The aP vaccine induced high antibodies and low adverse reactions and is composed of 5 B. pertussis antigens; Pertactin, Pertussis toxin, FHA, Fimbriae 2 (FIM 2) and Fimbriae 3 (FIM 3)87–89. The criteria used for selection of the antigens in the aP vaccine is based on pathogenesis. FHA, Pertactin and FIM 2 and 3 were selected due to their role in adherence to respiratory epithelial cells, whereas pertussis toxin is a systemic toxin that interferes with the function of G-protein coupled receptors in host cell membranes90–92. Additionally, in vivo experiments in animal models demonstrated that each antigen had some protective effect93.

Clinical trials conducted in Italy and Sweden demonstrated that the efficacy of the three-component (Pertactin, FHA, and pertussis toxin) and five-component aP vaccines is significantly higher when compared to the two-component vaccine (FHA and pertussis toxin)94. In a specific clinical trial in Sweden, involving 9829 infants aged 6–12 months, the efficacy of the five-component vaccine, containing FHA, FIM 2 and 3, pertussis toxin, and Pertactin, reached 85%. Conversely, the two-component vaccine in the same trial exhibited a lower efficacy of 59%. These trial results strongly suggest that Pertactin may play a crucial role in enhancing the effectiveness of licensed aP vaccines84. The inclusion of multiple antigens, known for their high immunogenicity and protective properties, could potentially mitigate the impact of antigenic variation, which can occur when relying on a single antigen alone95,96. Furthermore, vaccines containing multiple antigens provoke a broader and more comprehensive immune response compared to single-component vaccines. Investigations of the antibodies produced in response to aP vaccine antigens have revealed that they neutralized the activity of the toxin. Given that pertussis toxin is released into the extracellular milieu, it is thought that these antibodies are unlikely to facilitate complement-mediated killing and phagocytosis. Additionally, studies have shown that anti-Fim antibodies neutralize the function of FIM 2 and 3 by reducing the attachment of bacteria to host cells97,98.

Pertactin

Pertactin belongs to the Type 5a subclass of autotransporters79,82. After translocation of the passenger to the cell surface, the Pertactin precursor polypeptide is processed into a separate β-barrel domain and the passenger. The processed passenger, sometimes referred to as P.69, remains attached to the cell surface through a noncovalent interaction with the β-domain but can be released by mild heating99. Pertactin exhibits remarkable conservation across various Bordetella species and serves a crucial role in adhering to respiratory epithelial cells85,96,100. In vivo studies have demonstrated that Pertactin significantly contributes to pathogenesis by impeding the clearance of bacteria by neutrophils in the lungs85. The presence of high levels of anti-Pertactin IgG antibodies has been correlated with protection against B. pertussis101. A Pepscan analysis utilizing serum from both human and mouse subjects immunized with a Pertactin-containing vaccine, has revealed the specific epitopes on P.69 Pertactin to which protective antibodies bind102; the epitopes are shown in Fig. 4. The function of the protective antibodies varies depending on the immunogenic epitope of P.69 Pertactin the antibodies bind to. For example, the RGD motif of Pertactin is involved in adherence and antibodies to the RGD motif are likely to be neutralising in function; thus, preventing adhesion to the host. The antibodies that bind to P.69 Pertactin closer to the β-barrel domain are likely to facilitate complement-mediated killing. Furthermore, in vitro assays have demonstrated that antibodies targeting Pertactin possess bactericidal properties103. These antibodies bind to Pertactin, initiating the complement pathway, leading to the formation of the membrane attack complex (MAC), a critical component for bacterial lysis. The mechanism of action of Pertactin and the other components of the aP vaccine are shown in Fig. 5. Another potential mechanism for bactericidal action involves the deposition of C3b onto the bacterial cell surface. C3b is recognized by complement receptors (FcR) on phagocytes, thereby activating phagocytosis. This process represents a key immune mechanism for clearing B. pertussis from the respiratory tract104–106.Fig. 4 Structure of P.69 Pertactin with epitopes.

The crystal structure of P.69 Pertactin was retrieved from PDB (1DAB). The epitopes recognised by the human sera are shown in blue, epitopes recognised by mouse monoclonal antibodies (MAbs) are shown in yellow, and epitopes recognised by both human sera and MAbs are shown in red.

Fig. 5 Mechanism of action of acellular pertussis vaccine components.

a Pertussis toxin (PT) elicits neutralising antibodies b Antibodies to FIM 2 and FIM 3 decrease bacterial adherence. c Anti-Pertactin antibodies activate the complement complex C1q resulting in (1) phagocytosis of bacteria or (2) formation of a membrane attack complex (MAC) on the surface of the bacterial cell, leading to lysis of bacteria. d FHA is secreted into the supernatant and anti-FHA antibodies decrease bacterial adherence. The crystal structure for PT was retrieved from PDB 1PRT. The structure for Pertactin was retrieved from AlphaFold database, UniProt accession Q8RSU0. The crystal structures for the N-terminal region of the passenger and translocator domain of FHA were retrieved from PDB 1RWR and 4QKY, respectively. The figure was created using components from BioRender.com, Alphafold, and PDB.

Filamentous hemagglutinin

FHA, a 220-kDa protein, belongs to the Type 5b subclass of the T5SS, where fhaB encodes the TpsA protein, and fhaC encodes the TpsB protein77,107. This surface-localized protein plays a pivotal role in the pathogenesis of B. pertussis. In in vitro studies, FHA has been identified as an adhesin, facilitating the attachment of B. pertussis to host cells108. Furthermore, FHA is indispensable for the initial adherence and colonization of the trachea during in vivo infections109. Remarkably, mutants lacking FHA exhibit a notable inability to bind human neutrophils, and this deficiency cannot be compensated for by other B. pertussis adhesins110. In mouse models, it has been observed that Bordetella bronchiseptica lacking FHA triggers lung inflammation, whereas the wild-type strain does not. This suggests that FHA plays a pivotal role in modulating inflammation during infection, thereby contributing to bacterial persistence111. Additionally, FHA is actively involved in the up-regulation of two cytokines: IL-6 and the anti-inflammatory cytokine IL-10, while concurrently down-regulating IL-12, a pro-inflammatory cytokine that regulates the differentiation of Th1 cells112,113. Beyond its anti-inflammatory functions, FHA also fosters phagocytosis and promotes the induction of a Th2 immune response112,114. Given its surface localization and its role in virulence, various investigations have explored the potential of anti-FHA antibodies in safeguarding against infection. Mice that were immunized with FHA demonstrated significantly reduced bacterial counts in their lungs and trachea, with this protective effect being mediated by anti-FHA antibodies115. Studies in mice have additionally shown that while FHA antibodies alone offer relatively limited protection, combining FHA with other B. pertussis antigens enhances the immune response, resulting in more robust bacterial clearance in immunized mice116. Furthermore, immunization with B. pertussis proteins, including pertactin and FHA, has provided protection against other Bordetella strains such as B. bronchiseptica117. Consequently, FHA was incorporated into licensed vaccines.

Emerging resistance to aP

Despite the success of the aP in controlling infections, there is evidence of a resurgence in pertussis. This resurgence is primarily attributed to antigenic variations between the Pertactin types in the circulating strains and the strains used in the vaccine96. Such antigenic variation can potentially undermine the efficacy of the vaccine. Studies have indicated an increase in the isolation of Pertactin-deficient strains following aP vaccination, suggesting a bacterial evasion mechanism against the bactericidal antibodies induced by Pertactin in the vaccine103. Recently, clinical isolates lacking FHA have been identified, and this has been linked to the phenomenon of phase variation in FHA expression. Phase variation involves the reversible switching on and off of protein expression118. It has been proposed that phase variation plays a role in the pathogen’s adaptation to different environments, potentially diminishing the efficacy of the current aP vaccine119. Furthermore, existing licensed pertussis vaccines are effective in protecting against severe pertussis infections but provide limited defense against bacterial colonization. To address this limitation, there is a growing need to develop new vaccines that not only prevent colonization but also reduce disease severity. Research conducted in mice and baboon models has shown that the licensed aP vaccine primarily triggers a Th2 immune response and antibody production. In contrast, natural infection with B. pertussis and immunization with wPV elicits a Th1 and Th17 immune response114. As described previously, Th17 cells are important for vaccine mediated protection. One strategy to enhance the Th1/Th17 immune response is to combine the vaccine with adjuvants that stimulate the production of Th1/Th17 cells120. Some of the adjuvants known to elicit a Th1/Th17 immune response include squalene, CpG oligodeoxynucleotides (ODN), and outer membrane vesicles (OMVs)114,120,121. Studies have shown that immunisation of mice with bivalent OMVs isolated from S. Typhi and Salmonella Paratyphi A induced a Th1 and Th17 immune response suggesting the inclusion of OMVs into current aP vaccines may provoke an increased protective effect and decrease the ability of the bacterium to escape the protective effects of the vaccine122. Indeed, OMVs have been used in the licensed Bexsero vaccine and are known to elicit a robust antibody response along with Th1, Th2 and Th17 cells120.

Neisseria meningitidis serogroup B vaccine

N. meningitidis a Gram-negative bacterial pathogen, is responsible for causing meningitis and sepsis, particularly affecting children and young adults123. This bacterium is categorized into five pathogenic serogroups based on the composition of its bacterial capsule: A, B, C, Y, and W135. Polysaccharide conjugate vaccines have been effective against serogroups A, C, Y, and W135. However, due to concerns about potential autoimmune responses caused by cross-reactivity with human antigens, polysaccharide vaccines were not suitable for protection against serogroup B pathogens124. The Bexsero vaccine, represents a ground-breaking approach. It is a multicomponent vaccine that has received approval for use in Europe, Australia, and Canada. Remarkably, it is the first vaccine developed using the reverse vaccinology approach. This method involved analysing the complete genome sequence of N. meningitidis serogroup B strains to identify antigens secreted to the outer membrane. Antigens were selected based on their ability to induce serum bactericidal activity, a key indicator of protection, and their potential to offer cross-protection against a wide range of strains125,126. As noted above, the Bexsero vaccine includes four protein subunit antigens, one of which is the T5cSS adhesin NadA76 (Fig. 6). OMVs were added to the final formulation of the Bexsero vaccine to improve immunogenicity and strain coverage126.Fig. 6 Components of the Bexsero vaccine.

The licensed Bexsero vaccine is made up 3 Neisseria meningitidis antigens that were identified by reverse vaccinology and outer membrane vesicles (OMVs). The 3 antigens include NadA which belongs to the T5cSS, NHBA and fHbp which are lipoproteins. The crystal structure for the N-terminal region of the passenger of NadA was retrieved from PDB 6EUN and the translocator domain (residues 341–405) was generated using ColabFold194. The crystal structures for NHBA and fHbp were retrieved from PDB 2LFU and 3KVD, respectively. The figure was created using components from BioRender.com, ColabFold, and PDB.

Each antigen in the Bexsero vaccine triggers the production of antibodies that work synergistically to boost bactericidal activity. The inclusion of multiple antigens in the licensed vaccine was driven by the stronger bactericidal response observed when compared to using a single antigen alone. Clinical development data for the Bexsero vaccine suggest that antibodies against these antigens can confer protection by 1) activating the classical complement pathway and 2) preventing binding to the host cell surface83,127,128. A study by Biolchi et al. assessed the potential of the Bexsero vaccine to offer cross protection against non-MenB serogroups. This study involved testing non-MenB isolates from various countries using sera from infants vaccinated with Bexsero. The results showed that immunization with Bexsero induced complement-mediated killing and offered cross-protection against non-MenB strains129,130. Additionally, studies in mice and humans have shown that immunisation with Bexsero could provide cross-protection against Neisseria gonorrhoeae, by inducing complement-mediated killing131,132.

Neisseria adhesin A (NadA)

NadA is a trimeric autotransporter and is involved in adhesion and invasion of N. meningitidis into host tissues133. NadA is present in ~50% of all the diseases associated serogroups of N. meningitidis83. A study by Commanducci et al. has shown that NadA elicited high titres of bactericidal antibodies that cross react with all variants and elicited protection in laboratory animals83. Based on the peptide sequence homology of NadA, four variants have been identified which include: NadA-1, NadA-2/3, NadA-4/5 and NadA-6. The Bexsero vaccine includes the variant NadA-2/3, which is highly immunogenic and provides cross-protection across strains displaying NadA-1 and NadA-2/3134. In vivo studies have shown that during meningitis infection, NadA interacts with monocytes, macrophages and epithelial cells and stimulates the activation of pro-inflammatory cytokines such as TNF-α and IL-8135. NadA is a trimer and is made up of an N-terminal head domain involved in cell adhesion, a stalk domain and a C-terminal membrane anchor region required for translocation to the bacterial surface. A study by Giulani et al. showed that anti-NadA antibodies against the head region prevent adhesion to cells. This study suggested that NadA was a crucial component in the Bexsero vaccine and anti-NadA antibodies were likely to prevent initial colonisation by neutralising the function of NadA136,137.

T5ss proteins tested as vaccines

Resurgence of diseases, as seen in the case of pertussis, is a common phenomenon and is associated with antigenic variation and reduction in vaccine efficacy overtime. Hence, new vaccine antigens need to be identified. The B. pertussis T5SS proteins BrkA and Vag8 belong to the T5aSS subclass and help the bacterium evade complement-mediated killing. Since complement-mediated killing is responsible for protection against B. pertussis infection, inclusion of BrkA and Vag8 might help improved vaccine efficacy against pertussis. Two separate studies have shown that immunisation of mice with BrkA and Vag8 resulted in reduction in bacterial numbers, which was attributed to complement-mediated killing138,139. Furthermore, immunisation with BrkA alone was not sufficient for protection and had to be combined with other B. pertussis antigens FHA and PT139. Hence, identifying new antigens and the mechanisms involved in evasion might help develop better vaccines.

Vaccines are still lacking for many bacterial pathogens that infect humans and animals. Some of these pathogens have become resistant to multiple antibiotics and have been listed by the WHO as critical or high priority pathogens1. Hence, there is a need for the development of new therapeutics such as vaccines. The success of the T5SS proteins in the licensed acellular pertussis and Bexsero vaccines, and their wide distribution in Gram-negative bacteria, makes such proteins a rich hunting ground for vaccine antigens. Multiple studies have tested the potential of using T5SS proteins from different bacteria as vaccine antigens with varying success. The T5SS proteins tested (Table 2) in preclinical models showed varying degrees of protection against the relevant pathogen by blocking the functions of the pathogen. Some of the T5SS proteins such as DsrA against Haemophilus ducreyi, UspA1 and UspA2 against Haemophilus parasuis, SadA against S. Typhimurium, Pta against Proteus mirabilis showed only partial protection against infection140–143. Immunisation with Pta elicits antibodies that are neutralising in function. However, neutralising antibodies alone may not be involved in prevention or clearance of infection and other antibody mechanisms may be required. Therefore, the partial protection following immunisation with Pta might be attributed to neutralising antibodies alone. Inclusion of other antigens may be required to enhance protection and vaccine efficacy143. One study has shown that immunisation with a combination of T5SS proteins SigA, Pic and Sap showed more robust protection against Shigella flexneri than when used alone144. The licensed acellular pertussis and Bexsero vaccines include other antigens that are not T5SS proteins as well as OMVs. Since OMV production is a common phenomenon in Gram-negative bacteria and OMVs contain several surface antigens, the OMV vaccine platform can be used to enhance vaccine efficacy. Immunisation of chinchillas with a T5SS protein Hia in combination with OMVs showed protection against Nontypeable Haemophilus influenzae (NTHi)145. Hence, multiple antigen vaccines might work better than a single T5SS protein-based vaccine alone.Table 2 T5SS proteins tested as vaccines

Pathogen	Disease	Protein	Class	Function	Mechanism of protection	References	
Acinetobacter baumannii	Hospital acquired nosocomial infections	Ata	T5cSS	Biofilm formation, binding to ECM components such as laminin, collagen I, III, IV	Reduction in bacterial numbers seen in mouse model of pneumonia. Antibodies block binding to ECM component and mediate complement dependent bactericidal killing	167,168	
Actinobacillus pleuropneumoniae	Pleuropneumonia in pigs	Apa 2	T5cSS	Adhesion to host cells	Immunisation of mice with the head domain of Apa 2 resulted in >10-fold reduction in bacterial numbers. Neutralising antibodies, antibody-mediated and cell mediated immune response due to high levels of CD4+ and CD8+ T cells seen in immunised mice	169,170	
Bartonella spp.	Carrion’s diseases, cat scratch fever, trench fever	CFA	T5aSS	Cohemolytic activity	Reduction in bacterial numbers seen in mice immunised with CFA. Neutralising antibodies bind to CFA and prevent attachment to CFA	171	
Bordetella pertussis	Whooping cough	BrkA	T5aSS	Adhesion, serum resistance	Protection seen in mice when combined with other antigens (FHA and PT). Likely to be complement-mediated killing	138	
Bordetella pertussis	Whooping cough	FHA	T5bSS	Adhesion	Component of licensed acellular pertussis vaccine. Enhanced protection seen when used in combination with other B. pertussis antigens. Component of licensed acellular pertussis vaccine. Anti-FHA antibodies bind to FHA and decrease adherence	84	
Bordetella pertussis	Whooping cough	Pertactin	T5aSS	Adhesion	Integral component of licensed acellular pertussis vaccine. Complement mediated killing	85	
Bordetella pertussis	Whooping cough	SphB1	T5aSS	Protease	Reduction in bacterial numbers in the lower respiratory tract of immunised mice. Opsonisation and complement-mediated killing	139	
Bordetella pertussis	Whooping cough	Vag8	T5aSS	Serum resistance	Reduction in bacterial numbers in the lower respiratory tract of immunised mice. Opsonisation and complement-mediated killing	139	
Brucella suis	Swine and human brucellosis	BtaF	T5cSS	Binding to the ECM components	>10-fold reduction in bacterial numbers in the murine lungs. Neutralising antibodies that block adhesion of B. suis to the ECM	172,173	
Burkholderia pseudomallei	Melioidosis	BatA	T5aSS	Lipolytic activity	Immunisation of mice with PIV5-BatA resulted in complete protection against B. pseudomallei infection in the lungs and spleen. Antibody mediated protection	174,175	
Chlamydia trachomatis	Sexually transmitted infections	PmpD	T5bSS	Adhesion and induction of proinflammatory cytokines	No protection. Incorporation of multiple protein antigens might be needed to elicit a protective immune response	176,177	
Edwardsiella tarda	Belongs to the family Enterobacteriaceae and causes infection in fish	Tsh	T5aSS	Agglutination, biofilm formation and serum resistance	Immunisation with the passenger domain of Tsh induced protection in Japanese flounder. Serum specific antibodies	178	
Enterotoxigenic Escherichia coli (ETEC)	Diarrhea	Ag43	T5Ass	Involved in biofilm formation	Protection against intestinal colonisation seen in immunised mice. Antibody mediated protection	179,180	
Enterotoxigenic Escherichia coli (ETEC)	Diarrhea	EatA	T5aSS	Adhesion	Reduction in bacterial numbers in mice. Humoral and mucosal antibody response	181	
Enterotoxigenic Escherichia coli (ETEC)	Diarrhea	EptA	T5bSS	EptA and EatA are involved in adhesion	Reduction in bacterial numbers in mice. Humoral and mucosal antibody response	181	
Extraintestinal pathogenic E. coli (ExPEC)	Bacteraemia, neonatal meningitis, urinary tract infections (UTI)	SinH	T5eSS	Adherence and invasion	Reduction in bacterial numbers in immunised mice. High IgG, IgA antibody titres in immunised mice	182	
Haemophilus ducreyi	Chancroid	DsrA	T5cSS	Serum resistance, and adhesion to ECM proteins	Partial protection seen in swine model. Neutralising antibodies that block adhesion of H. ducreyi to ECM proteins	140	
Haemophilus influenzae	Pneumonia, meningitis, and bacteraemia	Hap	T5aSS	Adherence, invasion, microcolony formation	Formulation of hap with CT-E29H (modified cholera toxin used as an adjuvant) elicited a high immune response than with hap alone. Increase in IgG and IgA antibodies	183,184	
Haemophilus parasuis	Glässer’s disease in piglets	VtaA	T5cSS	Adhesion	Partial protection was seen in piglets immunised with VtaA. High IgG and IgA antibody titres	185	
Moraxella catarrhalis	Otitis, respiratory infections	UspA1 and UspA2	T5cSS	Adherence to epithelial cells and serum resistance	Partial protection seen in mouse model. Bactericidal antibodies that are cross protective against different strains of M. catarrhalis	141	
Neisseria meningitidis	Bacterial meningitis	NadA	T5cSS	Adhesion and invasion	Component in licensed Bexsero vaccine. Bactericidal antibodies	83	
Neisseria meningitidis	Bacterial meningitis	NhhA	T5cSS	Adhesion to host cells and ECM	Deletion of a single residue affects adhesion in vitro. NhhA induces bactericidal antibodies	186	
Nontypeable Haemophilus influenzae (NTHi)	Acute otitis media	Hia	T5cSS	Adhesion	Immunisation of chinchillas in combination with NTHi OMVs, HMW1 and HMW2 showed protection. Opsonophagocytosis	145	
Orientia tsutsugamushi	Scrub typhus	ScaA	T5aSS	Adhesion	Immunisation with ScaA provided protection against challenge in 40% of the mice. Neutralising antibodies	187	
Proteus mirabilis	UTI	Pta	T5aSS	Auto aggregation	Immunisation of mice resulted in 10-fold rection of bacterial numbers. IgG antibodies that were neutralising in function	143	
Pseudomonas aeruginosa	Pneumonia	AaaA	T5aSS	Aminopeptidase	Increased survival seen in mouse model of pneumonia when used in combination with other vaccine candidates. In vitro studies showed protein specific antibody when used in combination with other vaccine candidates	188	
Salmonella enterica	Gastroenteritis	SadA	T5cSS	Involved in adhesion, intestinal colonisation, and biofilm formation	10-fold reduction in bacterial numbers in mouse model. IgG antibodies	142	
Salmonella enterica	Gastroenteritis	MisL	T5aSS	Intestinal colonisation, biofilm formation and aggregation	10-fold reduction in bacterial numbers in immunised mice. Antibody mediated protection	189	
Shiga toxigenic Escherichia coli	Gastroenteritis	Saa	T5cSS	Adhesion	Anti-Saa antibodies that blocked adhesion	190	
Shigella flexneri	Shigellosis	IcsA	T5aSS	Adhesion, biofilm formation	Attenuated S. flexneri vaccine candidate SC602 (icsA deletion) provides protection in human. IgG and IgA antibodies	191	
Shigella flexneri	Shigellosis	Pic	T5aSS	Serum resistance and hemagglutination	Mice immunised via intranasal route with chimeric protein containing passenger domains of SigA, Pic and Sap showed highest protection. Robust humoral immune response characterised by increase in IgG, IgG1, IgG2a and IgM	144,192	
Shigella flexneri	Shigellosis	Sap	T5aSS	Biofilm formation	Mice immunised via intranasal route with chimeric protein containing passenger domains of SigA, Pic and Sap showed highest protection. Robust humoral immune response characterised by increase in IgG, IgG1, IgG2a and IgM	144,192	
Shigella flexneri	Shigellosis	SigA	T5aSS	Protease	Mice immunised via intranasal route with chimeric protein containing passenger domains of SigA, Pic and Sap showed highest protection. Robust humoral immune response characterised by increase in IgG, IgG1, IgG2a and IgM	144,192	
Yersinia pseudotuberculosis	Yersiniosis	YadA	T5cSS	Adhesion	Protection seen in mice immunised with YadA. Serum YadA specific-IgG antibodies	193	

Future perspectives

The T5SS proteins are targets for antibodies and their potential as vaccines is currently being tested against Gram-negative pathogens. Nevertheless, there is no single surface protein vaccine licensed against any bacterium. To date, studies that have tested the use of a single protein as a vaccine have shown varying success and only provide partial protection when used alone. Currently, the only single subunit vaccines that have proved successful are based on toxins and capsular polysaccharides. One reason for the lack of protection following immunisation with some antigens could be due to the way antibodies to that antigen interact with the bacterial surface. Gram-negative bacteria have LPS on the outer leaflet that is made up of lipid A, core oligosaccharide and O-Antigen. Studies have shown that that the O-Ag can provide steric hindrance and block the antibodies from accessing some antigens30. Indeed, immunisation with OMPs such as OmpA from S. Typhimurium and Salmonella Enteritidis does not confer protection30,146. Nevertheless, immunisation with OmpD from S. Typhimurium provides partial protection against infection with S. Typhimurium. In contrast, immunisation with S. Typhimurium OmpD confers minimal cross protection against S. Enteritidis. The lack of protection against S. Enteritidis is due to a single amino acid difference between OmpD of the two serovars30. The difference in protection between OmpA and OmpD has been postulated to be due to the footprint created by the antigens in the LPS layer. OmpD creates a larger footprint in the O-Ag layer, which results in less steric hindrance and allows the antibody access to the membrane proximal OmpD where it can initiate serum killing. In contrast, the OmpA generated footprint is too narrow to enable access of the OmpA antibody to its target30. Thus, multiple antigens are required to ensure protection against infection, as seen in the licensed Bexsero and acellular pertussis vaccines84,94.

While LPS provides steric hindrance preventing access of antibodies to membrane proximal epitopes, the passenger domain of T5SS proteins are largely predicted to extend beyond the LPS layer and to be accessible to antibody, including the S. Typhimurium T5cSS SadA protein142. Although multiple studies have tested the potential of using T5SS proteins as vaccine antigens; FHA, Pertactin and NadA are the only T5SS proteins used in licensed vaccines. The reason only a few T5SS proteins have been tested to date may be attributed to the fact that only some of these proteins have been functionally characterized and thus their role in virulence and as vaccine targets is still unknown. Moreover, research on the immune mechanism and function that correlates with protection is important for designing and licensing vaccines against emerging and multi-drug resistant bacterial pathogens. The success of all T5SS proteins (Table 1) at providing at least partial protection against infection, suggests that the combination of T5SS proteins with other surface antigens, as seen for the aP and Bexsero vaccines, is a useful strategy for creating vaccines for many Gram-negative bacterial infections, and, as is the case for Bexsero, the incorporation of OMVs is likely to enhance the protective effect of these antigens.

Finally, the T5SS has been utilised for the surface display of several recombinant proteins and antigens on the cell surface and has been termed as autodisplay. In this approach, the passenger domain of the T5SS is replaced with a heterologous protein that is transported and displayed on the cell surface. The autodisplay system is a promising tool for a range of biotechnological and biomedical applications including the development of vaccines147. The surface display of an epitope from Plasmodium falciparum on the surface of an attenuated S. enterica strain using the T5SS protein MisL was shown to induce a strong antibody response to the epitope148. Thus, the display of multiple immunogenic epitopes on the surface of an attenuated bacterial vector may be more cost-effective than formulations containing a mixture of single antigens. Additionally, OMVs could be engineered to express multiple antigens of choice, such as T5SS proteins. This would effectively reduce the cost for manufacturing and makes them ideal platforms for vaccine development53.

Acknowledgements

This work was supported by The University of Queensland Research Training Scholarship.

Author contributions

R.M.D.C. and I.R.H. contributed towards conception, drafting, and editing of the manuscript. J.L.R., T.J.W. and A.F.C. read and reviewed the manuscript. All authors read and approved the final manuscript.

Competing interests

The authors declare no competing interests.

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
==== Refs
References

1. WHO. List of bacteria for which new antibiotics are urgently needed (WHO News, 2019).
2. Murray CJ Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis Lancet 2022 399 629 655 10.1016/S0140-6736(21)02724-0 35065702
Murray, C. J. et al. Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis. Lancet 399, 629–655 (2022).35065702 10.1016/S0140-6736(21)02724-0
3. O’Neill, J. Tackling drug-resistant infections globally: final report and recommendations (Government of the United Kingdom, 2016).
4. Francis MJ Recent advances in vaccine technologies Vet. Clin. North Am. Small Anim. Pract. 2018 48 231 10.1016/j.cvsm.2017.10.002 29217317
Francis, M. J. Recent advances in vaccine technologies. Vet. Clin. North Am. Small Anim. Pract. 48, 231 (2018).29217317 10.1016/j.cvsm.2017.10.002
5. Jansen KU Anderson AS The role of vaccines in fighting antimicrobial resistance (AMR) Hum. Vaccin Immunother. 2018 14 2142 2149 10.1080/21645515.2018.1476814 29787323
Jansen, K. U. & Anderson, A. S. The role of vaccines in fighting antimicrobial resistance (AMR). Hum. Vaccin Immunother. 14, 2142–2149 (2018).29787323 10.1080/21645515.2018.1476814
6. WHO. Reported cases of vaccine prevenatble diseases (WHO, 2019).
7. Plotkin SA Correlates of protection induced by vaccination Clin. Vaccin. Immunol. 2010 17 1055 1065 10.1128/CVI.00131-10
Plotkin, S. A. Correlates of protection induced by vaccination. Clin. Vaccin. Immunol. 17, 1055–1065 (2010).10.1128/CVI.00131-10
8. Pollard AJ Bijker EM & Publisher Correction: A guide to vaccinology: from basic principles to new developments Nat. Rev. Immunol. 2021 21 129 10.1038/s41577-020-00497-5 33402728
Pollard, A. J. & Bijker, E. M. & Publisher Correction: A guide to vaccinology: from basic principles to new developments. Nat. Rev. Immunol. 21, 129 (2021).33402728 10.1038/s41577-020-00497-5
9. Poolman JT Expanding the role of bacterial vaccines into life-course vaccination strategies and prevention of antimicrobial-resistant infections NPJ Vaccines 2020 5 84 10.1038/s41541-020-00232-0 32963814
Poolman, J. T. Expanding the role of bacterial vaccines into life-course vaccination strategies and prevention of antimicrobial-resistant infections. NPJ Vaccines 5, 84 (2020).32963814 10.1038/s41541-020-00232-0
10. Clem AS Fundamentals of vaccine immunology J. Glob. Infect. Dis. 2011 3 73 78 10.4103/0974-777X.77299 21572612
Clem, A. S. Fundamentals of vaccine immunology. J. Glob. Infect. Dis. 3, 73–78 (2011).21572612 10.4103/0974-777X.77299
11. Golubovskaya, V. & Wu, L. Different subsets of T cells, memory, effector functions, and CAR-T immunotherapy. Cancers 8, 10.3390/cancers8030036 (2016).
12. Romagnani S Th1/Th2 cells Inflamm. Bowel Dis. 1999 5 285 294 10.1097/00054725-199911000-00009 10579123
Romagnani, S. Th1/Th2 cells. Inflamm. Bowel Dis. 5, 285–294 (1999).10579123 10.1097/00054725-199911000-00009
13. Rivera-Hernandez, T. et al. Vaccine-induced Th1-type response protects against invasive Group A Streptococcus infection in the absence of opsonizing antibodies. mBio 11, 10.1128/mBio.00122-20 (2020).
14. Crotty S T follicular helper cell differentiation, function, and roles in disease Immunity 2014 41 529 542 10.1016/j.immuni.2014.10.004 25367570
Crotty, S. T follicular helper cell differentiation, function, and roles in disease. Immunity 41, 529–542 (2014).25367570 10.1016/j.immuni.2014.10.004
15. Schroeder HW Jr Cavacini L Structure and function of immunoglobulins J. Allergy Clin. Immunol. 2010 125 S41 S52 10.1016/j.jaci.2009.09.046 20176268
Schroeder, H. W. Jr & Cavacini, L. Structure and function of immunoglobulins. J. Allergy Clin. Immunol. 125, S41–S52 (2010).20176268 10.1016/j.jaci.2009.09.046
16. Sharp TH Insights into IgM-mediated complement activation based on in situ structures of IgM-C1-C4b Proc. Natl Acad. Sci. 2019 116 11900 11905 10.1073/pnas.1901841116 31147461
Sharp, T. H. et al. Insights into IgM-mediated complement activation based on in situ structures of IgM-C1-C4b. Proc. Natl Acad. Sci. 116, 11900–11905 (2019).31147461 10.1073/pnas.1901841116
17. Alugupalli AS The lack of natural IgM increases susceptibility and impairs anti-Vi polysaccharide IgG responses in a mouse model of typhoid Immunohorizons 2022 6 807 816 10.4049/immunohorizons.2200088 36480484
Alugupalli, A. S. et al. The lack of natural IgM increases susceptibility and impairs anti-Vi polysaccharide IgG responses in a mouse model of typhoid. Immunohorizons 6, 807–816 (2022).36480484 10.4049/immunohorizons.2200088
18. Gil-Cruz C The porin OmpD from nontyphoidal Salmonella is a key target for a protective B1b cell antibody response Proc. Natl Acad. Sci. USA 2009 106 9803 9808 10.1073/pnas.0812431106 19487686
Gil-Cruz, C. et al. The porin OmpD from nontyphoidal Salmonella is a key target for a protective B1b cell antibody response. Proc. Natl Acad. Sci. USA 106, 9803–9808 (2009).19487686 10.1073/pnas.0812431106
19. Vidarsson G Dekkers G Rispens T IgG subclasses and allotypes: from structure to effector functions Front. Immunol. 2014 5 520 10.3389/fimmu.2014.00520 25368619
Vidarsson, G., Dekkers, G. & Rispens, T. IgG subclasses and allotypes: from structure to effector functions. Front. Immunol. 5, 520 (2014).25368619 10.3389/fimmu.2014.00520
20. Dangl JL Segmental flexibility and complement fixation of genetically engineered chimeric human, rabbit and mouse antibodies EMBO J. 1988 7 1989 1994 10.1002/j.1460-2075.1988.tb03037.x 3138110
Dangl, J. L. et al. Segmental flexibility and complement fixation of genetically engineered chimeric human, rabbit and mouse antibodies. EMBO J. 7, 1989–1994 (1988).3138110 10.1002/j.1460-2075.1988.tb03037.x
21. Goh YS Human IgG isotypes and activating Fcγ receptors in the interaction of Salmonella enterica serovar Typhimurium with phagocytic cells Immunology 2011 133 74 83 10.1111/j.1365-2567.2011.03411.x 21323662
Goh, Y. S. et al. Human IgG isotypes and activating Fcγ receptors in the interaction of Salmonella enterica serovar Typhimurium with phagocytic cells. Immunology 133, 74–83 (2011).21323662 10.1111/j.1365-2567.2011.03411.x
22. Maguire GA Kumararatne DS Joyce HJ Are there any clinical indications for measuring IgG subclasses? Ann. Clin. Biochem. 2002 39 374 377 10.1258/000456302760042678 12117441
Maguire, G. A., Kumararatne, D. S. & Joyce, H. J. Are there any clinical indications for measuring IgG subclasses? Ann. Clin. Biochem. 39, 374–377 (2002).12117441 10.1258/000456302760042678
23. Kuijpers TW Weening RS Out TA IgG subclass deficiencies and recurrent pyogenic infections, unresponsiveness against bacterial polysaccharide antigens Allergol. Immunopathol. 1992 20 28 34
Kuijpers, T. W., Weening, R. S. & Out, T. A. IgG subclass deficiencies and recurrent pyogenic infections, unresponsiveness against bacterial polysaccharide antigens. Allergol. Immunopathol. 20, 28–34 (1992).
24. Vidarsson G Isotypes and opsonophagocytosis of pneumococcus type 6B antibodies elicited in infants and adults by an experimental pneumococcus type 6B-tetanus toxoid vaccine Infect. Immun. 1998 66 2866 2870 10.1128/IAI.66.6.2866-2870.1998 9596761
Vidarsson, G. et al. Isotypes and opsonophagocytosis of pneumococcus type 6B antibodies elicited in infants and adults by an experimental pneumococcus type 6B-tetanus toxoid vaccine. Infect. Immun. 66, 2866–2870 (1998).9596761 10.1128/IAI.66.6.2866-2870.1998
25. James LK Till SJ Potential mechanisms for IgG4 inhibition of immediate hypersensitivity reactions Curr. Allergy Asthma Rep. 2016 16 23 10.1007/s11882-016-0600-2 26892721
James, L. K. & Till, S. J. Potential mechanisms for IgG4 inhibition of immediate hypersensitivity reactions. Curr. Allergy Asthma Rep. 16, 23 (2016).26892721 10.1007/s11882-016-0600-2
26. French MA Harrison G An investigation into the effect of the IgG antibody system on the susceptibility of IgA-deficient patients to respiratory tract infections Clin. Exp. Immunol. 1986 66 640 647 3568451
French, M. A. & Harrison, G. An investigation into the effect of the IgG antibody system on the susceptibility of IgA-deficient patients to respiratory tract infections. Clin. Exp. Immunol. 66, 640–647 (1986).3568451
27. Wells TJ Increased severity of respiratory infections associated with elevated anti-LPS IgG2 which inhibits serum bactericidal killing J. Exp. Med. 2014 211 1893 1904 10.1084/jem.20132444 25113975
Wells, T. J. et al. Increased severity of respiratory infections associated with elevated anti-LPS IgG2 which inhibits serum bactericidal killing. J. Exp. Med. 211, 1893–1904 (2014).25113975 10.1084/jem.20132444
28. Bianchi A Fantoni S Prugnola A Meningococcal B vaccine and the vision of a meningitis free world J. Prev. Med Hyg. 2015 56 E140 E143 26788735
Bianchi, A., Fantoni, S. & Prugnola, A. Meningococcal B vaccine and the vision of a meningitis free world. J. Prev. Med Hyg. 56, E140–E143 (2015).26788735
29. Nix EB Risk of invasive Haemophilus influenzae type b (Hib) disease in adults with secondary immunodeficiency in the post-Hib vaccine era Clin. Vaccin. Immunol. 2012 19 766 771 10.1128/CVI.05675-11
Nix, E. B. et al. Risk of invasive Haemophilus influenzae type b (Hib) disease in adults with secondary immunodeficiency in the post-Hib vaccine era. Clin. Vaccin. Immunol. 19, 766–771 (2012).10.1128/CVI.05675-11
30. Domínguez-Medina CC Outer membrane protein size and LPS O-antigen define protective antibody targeting to the Salmonella surface Nat. Commun. 2020 11 851 10.1038/s41467-020-14655-9 32051408
Domínguez-Medina, C. C. et al. Outer membrane protein size and LPS O-antigen define protective antibody targeting to the Salmonella surface. Nat. Commun. 11, 851 (2020).32051408 10.1038/s41467-020-14655-9
31. MacLennan CA Dysregulated humoral immunity to nontyphoidal Salmonella in HIV-infected African adults Science 2010 328 508 512 10.1126/science.1180346 20413503
MacLennan, C. A. et al. Dysregulated humoral immunity to nontyphoidal Salmonella in HIV-infected African adults. Science 328, 508–512 (2010).20413503 10.1126/science.1180346
32. Coggon, C. F. et al. A novel method of serum resistance by Escherichia coli that causes urosepsis. mBio 9, 10.1128/mBio.00920-18 (2018).
33. Döring G Meisner C Stern M A double-blind randomized placebo-controlled phase III study of a Pseudomonas aeruginosa flagella vaccine in cystic fibrosis patients Proc. Natl Acad. Sci. USA 2007 104 11020 11025 10.1073/pnas.0702403104 17585011
Döring, G., Meisner, C. & Stern, M. A double-blind randomized placebo-controlled phase III study of a Pseudomonas aeruginosa flagella vaccine in cystic fibrosis patients. Proc. Natl Acad. Sci. USA 104, 11020–11025 (2007).17585011 10.1073/pnas.0702403104
34. Chen WH Single-dose live oral cholera vaccine CVD 103-HgR protects against human experimental infection with Vibrio cholerae O1 El Tor Clin. Infect. Dis. 2016 62 1329 1335 10.1093/cid/ciw145 27001804
Chen, W. H. et al. Single-dose live oral cholera vaccine CVD 103-HgR protects against human experimental infection with Vibrio cholerae O1 El Tor. Clin. Infect. Dis. 62, 1329–1335 (2016).27001804 10.1093/cid/ciw145
35. Tennant SM Levine MM Live attenuated vaccines for invasive Salmonella infections Vaccine 2015 33 C36 C41 10.1016/j.vaccine.2015.04.029 25902362
Tennant, S. M. & Levine, M. M. Live attenuated vaccines for invasive Salmonella infections. Vaccine 33, C36–C41 (2015).25902362 10.1016/j.vaccine.2015.04.029
36. Taylor DN Evaluation of a bivalent (CVD 103-HgR/CVD 111) live oral cholera vaccine in adult volunteers from the United States and Peru Infect. Immun. 1997 65 3852 3856 10.1128/iai.65.9.3852-3856.1997 9284163
Taylor, D. N. et al. Evaluation of a bivalent (CVD 103-HgR/CVD 111) live oral cholera vaccine in adult volunteers from the United States and Peru. Infect. Immun. 65, 3852–3856 (1997).9284163 10.1128/iai.65.9.3852-3856.1997
37. Frey J Biological safety concepts of genetically modified live bacterial vaccines Vaccine 2007 25 5598 5605 10.1016/j.vaccine.2006.11.058 17239999
Frey, J. Biological safety concepts of genetically modified live bacterial vaccines. Vaccine 25, 5598–5605 (2007).17239999 10.1016/j.vaccine.2006.11.058
38. Crump JA Mintz ED Global trends in typhoid and paratyphoid fever Clin. Infect. Dis. 2010 50 241 246 10.1086/649541 20014951
Crump, J. A. & Mintz, E. D. Global trends in typhoid and paratyphoid fever. Clin. Infect. Dis. 50, 241–246 (2010).20014951 10.1086/649541
39. Fraser A Paul M Goldberg E Acosta CJ Leibovici L Typhoid fever vaccines: systematic review and meta-analysis of randomised controlled trials Vaccine 2007 25 7848 7857 10.1016/j.vaccine.2007.08.027 17928109
Fraser, A., Paul, M., Goldberg, E., Acosta, C. J. & Leibovici, L. Typhoid fever vaccines: systematic review and meta-analysis of randomised controlled trials. Vaccine 25, 7848–7857 (2007).17928109 10.1016/j.vaccine.2007.08.027
40. Engels EA Falagas ME Lau J Bennish ML Typhoid fever vaccines: a meta-analysis of studies on efficacy and toxicity BMJ 1998 316 110 116 10.1136/bmj.316.7125.110 9462316
Engels, E. A., Falagas, M. E., Lau, J. & Bennish, M. L. Typhoid fever vaccines: a meta-analysis of studies on efficacy and toxicity. BMJ 316, 110–116 (1998).9462316 10.1136/bmj.316.7125.110
41. Ryan M Distinct T-cell subtypes induced with whole cell and acellular pertussis vaccines in children Immunology 1998 93 1 10 10.1046/j.1365-2567.1998.00401.x 9536112
Ryan, M. et al. Distinct T-cell subtypes induced with whole cell and acellular pertussis vaccines in children. Immunology 93, 1–10 (1998).9536112 10.1046/j.1365-2567.1998.00401.x
42. Jefferson T Rudin M DiPietrantonj C Systematic review of the effects of pertussis vaccines in children Vaccine 2003 21 2003 2014 10.1016/S0264-410X(02)00770-3 12706690
Jefferson, T., Rudin, M. & DiPietrantonj, C. Systematic review of the effects of pertussis vaccines in children. Vaccine 21, 2003–2014 (2003).12706690 10.1016/S0264-410X(02)00770-3
43. van der Lee S Hendrikx LH Sanders EAM Berbers GAM Buisman AM Whole-cell or acellular pertussis primary immunizations in infancy determines adolescent cellular immune profiles Front. Immunol. 2018 9 51 10.3389/fimmu.2018.00051 29416544
van der Lee, S., Hendrikx, L. H., Sanders, E. A. M., Berbers, G. A. M. & Buisman, A. M. Whole-cell or acellular pertussis primary immunizations in infancy determines adolescent cellular immune profiles. Front. Immunol. 9, 51 (2018).29416544 10.3389/fimmu.2018.00051
44. Muloiwa R Kagina BM Engel ME Hussey GD The burden of pertussis in low- and middle-income countries since the inception of the Expanded Programme on Immunization (EPI) in 1974: a systematic review protocol Syst. Rev. 2015 4 62 10.1186/s13643-015-0053-z 25930111
Muloiwa, R., Kagina, B. M., Engel, M. E. & Hussey, G. D. The burden of pertussis in low- and middle-income countries since the inception of the Expanded Programme on Immunization (EPI) in 1974: a systematic review protocol. Syst. Rev. 4, 62 (2015).25930111 10.1186/s13643-015-0053-z
45. Cress BF Masquerading microbial pathogens: capsular polysaccharides mimic host-tissue molecules FEMS Microbiol. Rev. 2014 38 660 697 10.1111/1574-6976.12056 24372337
Cress, B. F. et al. Masquerading microbial pathogens: capsular polysaccharides mimic host-tissue molecules. FEMS Microbiol. Rev. 38, 660–697 (2014).24372337 10.1111/1574-6976.12056
46. Horwitz MA Silverstein SC Influence of the Escherichia coli capsule on complement fixation and on phagocytosis and killing by human phagocytes J. Clin. Invest. 1980 65 82 94 10.1172/JCI109663 6985617
Horwitz, M. A. & Silverstein, S. C. Influence of the Escherichia coli capsule on complement fixation and on phagocytosis and killing by human phagocytes. J. Clin. Invest. 65, 82–94 (1980).6985617 10.1172/JCI109663
47. MacLennan CA Martin LB Micoli F Vaccines against invasive Salmonella disease: current status and future directions Hum. Vaccin. Immunother. 2014 10 1478 1493 10.4161/hv.29054 24804797
MacLennan, C. A., Martin, L. B. & Micoli, F. Vaccines against invasive Salmonella disease: current status and future directions. Hum. Vaccin. Immunother. 10, 1478–1493 (2014).24804797 10.4161/hv.29054
48. Prinz DM Smithson SL Kieber-Emmons T Westerink MA Induction of a protective capsular polysaccharide antibody response to a multiepitope DNA vaccine encoding a peptide mimic of meningococcal serogroup C capsular polysaccharide Immunology 2003 110 242 249 10.1046/j.1365-2567.2003.01732.x 14511238
Prinz, D. M., Smithson, S. L., Kieber-Emmons, T. & Westerink, M. A. Induction of a protective capsular polysaccharide antibody response to a multiepitope DNA vaccine encoding a peptide mimic of meningococcal serogroup C capsular polysaccharide. Immunology 110, 242–249 (2003).14511238 10.1046/j.1365-2567.2003.01732.x
49. Ada G Isaacs D Carbohydrate-protein conjugate vaccines Clin. Microbiol. Infect. 2003 9 79 85 10.1046/j.1469-0691.2003.00530.x 12588327
Ada, G. & Isaacs, D. Carbohydrate-protein conjugate vaccines. Clin. Microbiol. Infect. 9, 79–85 (2003).12588327 10.1046/j.1469-0691.2003.00530.x
50. Buchwald UK Sequential administration of Prevnar 13™ and PNEUMOVAX™ 23 in healthy participants 50 years of age and older Hum. Vaccin. Immunother. 2021 17 2678 2690 10.1080/21645515.2021.1888621 34019468
Buchwald, U. K. et al. Sequential administration of Prevnar 13™ and PNEUMOVAX™ 23 in healthy participants 50 years of age and older. Hum. Vaccin. Immunother. 17, 2678–2690 (2021).34019468 10.1080/21645515.2021.1888621
51. Jossi SE Vi polysaccharide and conjugated vaccines afford similar early, IgM or IgG-independent control of infection but boosting with conjugated Vi vaccines sustains the efficacy of immune responses Front. Immunol. 2023 14 1139329 10.3389/fimmu.2023.1139329 37033932
Jossi, S. E. et al. Vi polysaccharide and conjugated vaccines afford similar early, IgM or IgG-independent control of infection but boosting with conjugated Vi vaccines sustains the efficacy of immune responses. Front. Immunol. 14, 1139329 (2023).37033932 10.3389/fimmu.2023.1139329
52. Chen DJ Delivery of foreign antigens by engineered outer membrane vesicle vaccines Proc. Natl Acad. Sci. USA 2010 107 3099 3104 10.1073/pnas.0805532107 20133740
Chen, D. J. et al. Delivery of foreign antigens by engineered outer membrane vesicle vaccines. Proc. Natl Acad. Sci. USA 107, 3099–3104 (2010).20133740 10.1073/pnas.0805532107
53. van der Pol L Stork M van der Ley P Outer membrane vesicles as platform vaccine technology Biotechnol. J. 2015 10 1689 1706 10.1002/biot.201400395 26912077
van der Pol, L., Stork, M. & van der Ley, P. Outer membrane vesicles as platform vaccine technology. Biotechnol. J. 10, 1689–1706 (2015).26912077 10.1002/biot.201400395
54. Beernink, P. T., Vianzon, V., Lewis, L. A., Moe, G. R. & Granoff, D. M. A Meningococcal outer membrane vesicle vaccine with overexpressed mutant fHbp elicits higher protective antibody responses in infant rhesus macaques than a licensed serogroup B vaccine. mBio 10, 10.1128/mBio.01231-19 (2019).
55. Sierra GV Vaccine against group B Neisseria meningitidis: protection trial and mass vaccination results in Cuba NIPH Ann. 1991 14 195 207 1812432
Sierra, G. V. et al. Vaccine against group B Neisseria meningitidis: protection trial and mass vaccination results in Cuba. NIPH Ann. 14, 195–207 (1991).1812432
56. de Moraes JC Protective efficacy of a serogroup B meningococcal vaccine in Sao Paulo, Brazil Lancet 1992 340 1074 1078 10.1016/0140-6736(92)93086-3 1357461
de Moraes, J. C. et al. Protective efficacy of a serogroup B meningococcal vaccine in Sao Paulo, Brazil. Lancet 340, 1074–1078 (1992).1357461 10.1016/0140-6736(92)93086-3
57. Bjune G Effect of outer membrane vesicle vaccine against group B meningococcal disease in Norway Lancet 1991 338 1093 1096 10.1016/0140-6736(91)91961-S 1682541
Bjune, G. et al. Effect of outer membrane vesicle vaccine against group B meningococcal disease in Norway. Lancet 338, 1093–1096 (1991).1682541 10.1016/0140-6736(91)91961-S
58. Kelly C Arnold R Galloway Y O’Hallahan J A prospective study of the effectiveness of the New Zealand meningococcal B vaccine Am. J. Epidemiol. 2007 166 817 823 10.1093/aje/kwm147 17615088
Kelly, C., Arnold, R., Galloway, Y. & O’Hallahan, J. A prospective study of the effectiveness of the New Zealand meningococcal B vaccine. Am. J. Epidemiol. 166, 817–823 (2007).17615088 10.1093/aje/kwm147
59. Holst J Vaccines against meningococcal serogroup B disease containing outer membrane vesicles (OMV): lessons from past programs and implications for the future Hum. Vaccin Immunother. 2013 9 1241 1253 10.4161/hv.24129 23857274
Holst, J. et al. Vaccines against meningococcal serogroup B disease containing outer membrane vesicles (OMV): lessons from past programs and implications for the future. Hum. Vaccin Immunother. 9, 1241–1253 (2013).23857274 10.4161/hv.24129
60. Serruto D Bottomley MJ Ram S Giuliani MM Rappuoli R The new multicomponent vaccine against meningococcal serogroup B, 4CMenB: immunological, functional and structural characterization of the antigens Vaccine 2012 30 B87 B97 10.1016/j.vaccine.2012.01.033 22607904
Serruto, D., Bottomley, M. J., Ram, S., Giuliani, M. M. & Rappuoli, R. The new multicomponent vaccine against meningococcal serogroup B, 4CMenB: immunological, functional and structural characterization of the antigens. Vaccine 30, B87–B97 (2012).22607904 10.1016/j.vaccine.2012.01.033
61. Wedege E Functional and specific antibody responses in adult volunteers in new zealand who were given one of two different meningococcal serogroup B outer membrane vesicle vaccines Clin. Vaccin. Immunol. 2007 14 830 838 10.1128/CVI.00039-07
Wedege, E. et al. Functional and specific antibody responses in adult volunteers in new zealand who were given one of two different meningococcal serogroup B outer membrane vesicle vaccines. Clin. Vaccin. Immunol. 14, 830–838 (2007).10.1128/CVI.00039-07
62. Bottero D Characterization of the immune response induced by pertussis OMVs-based vaccine Vaccine 2016 34 3303 3309 10.1016/j.vaccine.2016.04.079 27151884
Bottero, D. et al. Characterization of the immune response induced by pertussis OMVs-based vaccine. Vaccine 34, 3303–3309 (2016).27151884 10.1016/j.vaccine.2016.04.079
63. Baker JL Chen L Rosenthal JA Putnam D DeLisa MP Microbial biosynthesis of designer outer membrane vesicles Curr. Opin. Biotechnol. 2014 29 76 84 10.1016/j.copbio.2014.02.018 24667098
Baker, J. L., Chen, L., Rosenthal, J. A., Putnam, D. & DeLisa, M. P. Microbial biosynthesis of designer outer membrane vesicles. Curr. Opin. Biotechnol. 29, 76–84 (2014).24667098 10.1016/j.copbio.2014.02.018
64. Kim SH Structural modifications of outer membrane vesicles to refine them as vaccine delivery vehicles Biochim. Biophys. Acta 2009 1788 2150 2159 10.1016/j.bbamem.2009.08.001 19695218
Kim, S. H. et al. Structural modifications of outer membrane vesicles to refine them as vaccine delivery vehicles. Biochim. Biophys. Acta 1788, 2150–2159 (2009).19695218 10.1016/j.bbamem.2009.08.001
65. Pastor Y Towards a subunit vaccine from a Shigella flexneri ΔtolR mutant Vaccine 2018 36 7509 7519 10.1016/j.vaccine.2018.10.066 30420041
Pastor, Y. et al. Towards a subunit vaccine from a Shigella flexneri ΔtolR mutant. Vaccine 36, 7509–7519 (2018).30420041 10.1016/j.vaccine.2018.10.066
66. Liu Q Outer membrane vesicles from flagellin-deficient Salmonella enterica serovar Typhimurium induce cross-reactive immunity and provide cross-protection against heterologous Salmonella challenge Sci. Rep. 2016 6 34776 10.1038/srep34776 27698383
Liu, Q. et al. Outer membrane vesicles from flagellin-deficient Salmonella enterica serovar Typhimurium induce cross-reactive immunity and provide cross-protection against heterologous Salmonella challenge. Sci. Rep. 6, 34776 (2016).27698383 10.1038/srep34776
67. Liu Q Outer membrane vesicles derived from Salmonella Typhimurium mutants with truncated LPS induce cross-protective immune responses against infection of Salmonella enterica serovars in the mouse model Int. J. Med. Microbiol. 2016 306 697 706 10.1016/j.ijmm.2016.08.004 27578609
Liu, Q. et al. Outer membrane vesicles derived from Salmonella Typhimurium mutants with truncated LPS induce cross-protective immune responses against infection of Salmonella enterica serovars in the mouse model. Int. J. Med. Microbiol. 306, 697–706 (2016).27578609 10.1016/j.ijmm.2016.08.004
68. Gerke C Production of a Shigella sonnei vaccine based on generalized modules for membrane antigens (GMMA), 1790GAHB PLoS One 2015 10 e0134478 10.1371/journal.pone.0134478 26248044
Gerke, C. et al. Production of a Shigella sonnei vaccine based on generalized modules for membrane antigens (GMMA), 1790GAHB. PLoS One 10, e0134478 (2015).26248044 10.1371/journal.pone.0134478
69. Ausiello CM Acellular vaccines induce cell-mediated immunity to Bordetella pertussis antigens in infants undergoing primary vaccination against pertussis Dev. Biol. Stand 1997 89 315 320 9272365
Ausiello, C. M. et al. Acellular vaccines induce cell-mediated immunity to Bordetella pertussis antigens in infants undergoing primary vaccination against pertussis. Dev. Biol. Stand 89, 315–320 (1997).9272365
70. Hodges FJ Von Vergel LT Cunningham AF Henderson IR Icke C Redefining the bacterial Type I protein secretion system Adv. Microb. Physiol. 2023 82 155 204 10.1016/bs.ampbs.2022.10.003 36948654
Hodges, F. J., Von Vergel, L. T., Cunningham, A. F., Henderson, I. R. & Icke, C. Redefining the bacterial Type I protein secretion system. Adv. Microb. Physiol. 82, 155–204 (2023).36948654 10.1016/bs.ampbs.2022.10.003
71. Costa TR Secretion systems in Gram-negative bacteria: structural and mechanistic insights Nat. Rev. Microbiol. 2015 13 343 359 10.1038/nrmicro3456 25978706
Costa, T. R. et al. Secretion systems in Gram-negative bacteria: structural and mechanistic insights. Nat. Rev. Microbiol. 13, 343–359 (2015).25978706 10.1038/nrmicro3456
72. Christie PJ The rich tapestry of bacterial protein translocation systems Protein J. 2019 38 389 408 10.1007/s10930-019-09862-3 31407127
Christie, P. J. The rich tapestry of bacterial protein translocation systems. Protein J. 38, 389–408 (2019).31407127 10.1007/s10930-019-09862-3
73. Palmer T Finney AJ Saha CK Atkinson GC Sargent F A holin/peptidoglycan hydrolase-dependent protein secretion system Mol. Microbiol. 2021 115 345 355 10.1111/mmi.14599 32885520
Palmer, T., Finney, A. J., Saha, C. K., Atkinson, G. C. & Sargent, F. A holin/peptidoglycan hydrolase-dependent protein secretion system. Mol. Microbiol. 115, 345–355 (2021).32885520 10.1111/mmi.14599
74. Grossman AS Mauer TJ Forest KT Goodrich-Blair H A widespread bacterial secretion system with diverse substrates mBio 2021 12 e0195621 10.1128/mBio.01956-21 34399622
Grossman, A. S., Mauer, T. J., Forest, K. T. & Goodrich-Blair, H. A widespread bacterial secretion system with diverse substrates. mBio 12, e0195621 (2021).34399622 10.1128/mBio.01956-21
75. Dewan, K. K., Linz, B., DeRocco, S. E. & Harvill, E. T. Acellular pertussis vaccine components: today and tomorrow. Vaccines 8, 10.3390/vaccines8020217 (2020).
76. Gorringe AR Pajón R Bexsero: a multicomponent vaccine for prevention of meningococcal disease Hum. Vaccines Immunotherapeutics 2012 8 174 183 10.4161/hv.18500
Gorringe, A. R. & Pajón, R. Bexsero: a multicomponent vaccine for prevention of meningococcal disease. Hum. Vaccines Immunotherapeutics 8, 174–183 (2012).10.4161/hv.18500
77. Henderson IR Navarro-Garcia F Desvaux M Fernandez RC Ala’Aldeen D Type V protein secretion pathway: the autotransporter story Microbiol. Mol. Biol. Rev. 2004 68 692 744 10.1128/MMBR.68.4.692-744.2004 15590781
Henderson, I. R., Navarro-Garcia, F., Desvaux, M., Fernandez, R. C. & Ala’Aldeen, D. Type V protein secretion pathway: the autotransporter story. Microbiol. Mol. Biol. Rev. 68, 692–744 (2004).15590781 10.1128/MMBR.68.4.692-744.2004
78. Meuskens I Saragliadis A Leo JC Linke D Type V secretion systems: an overview of passenger domain functions Front. Microbiol 2019 10 1163 10.3389/fmicb.2019.01163 31214135
Meuskens, I., Saragliadis, A., Leo, J. C. & Linke, D. Type V secretion systems: an overview of passenger domain functions. Front. Microbiol 10, 1163 (2019).31214135 10.3389/fmicb.2019.01163
79. Desvaux M Parham NJ Henderson IR The autotransporter secretion system Res. Microbiol. 2004 155 53 60 10.1016/j.resmic.2003.10.002 14990256
Desvaux, M., Parham, N. J. & Henderson, I. R. The autotransporter secretion system. Res. Microbiol. 155, 53–60 (2004).14990256 10.1016/j.resmic.2003.10.002
80. Henderson IR Renaming protein secretion in the gram-negative bacteria Trends Microbiol. 2000 8 352 10.1016/S0966-842X(00)01814-X 11041650
Henderson, I. R. et al. Renaming protein secretion in the gram-negative bacteria. Trends Microbiol. 8, 352 (2000).11041650 10.1016/S0966-842X(00)01814-X
81. Leo JC Grin I Linke D Type V secretion: mechanism (s) of autotransport through the bacterial outer membrane Philos. Trans. R. Soc. B Biol. Sci. 2012 367 1088 1101 10.1098/rstb.2011.0208
Leo, J. C., Grin, I. & Linke, D. Type V secretion: mechanism (s) of autotransport through the bacterial outer membrane. Philos. Trans. R. Soc. B Biol. Sci. 367, 1088–1101 (2012).10.1098/rstb.2011.0208
82. Henderson IR Navarro-Garcia F Nataro JP The great escape: structure and function of the autotransporter proteins Trends Microbiol. 1998 6 370 378 10.1016/S0966-842X(98)01318-3 9778731
Henderson, I. R., Navarro-Garcia, F. & Nataro, J. P. The great escape: structure and function of the autotransporter proteins. Trends Microbiol. 6, 370–378 (1998).9778731 10.1016/S0966-842X(98)01318-3
83. Comanducci M NadA, a novel vaccine candidate of Neisseria meningitidis J. Exp. Med. 2002 195 1445 1454 10.1084/jem.20020407 12045242
Comanducci, M. et al. NadA, a novel vaccine candidate of Neisseria meningitidis. J. Exp. Med. 195, 1445–1454 (2002).12045242 10.1084/jem.20020407
84. Gustafsson L Hallander HO Olin P Reizenstein E Storsaeter J A controlled trial of a two-component acellular, a five-component acellular, and a whole-cell pertussis vaccine N. Engl. J. Med. 1996 334 349 356 10.1056/NEJM199602083340602 8538705
Gustafsson, L., Hallander, H. O., Olin, P., Reizenstein, E. & Storsaeter, J. A controlled trial of a two-component acellular, a five-component acellular, and a whole-cell pertussis vaccine. N. Engl. J. Med. 334, 349–356 (1996).8538705 10.1056/NEJM199602083340602
85. Inatsuka CS Pertactin is required for Bordetella species to resist neutrophil-mediated clearance Infect. Immun. 2010 78 2901 2909 10.1128/IAI.00188-10 20421378
Inatsuka, C. S. et al. Pertactin is required for Bordetella species to resist neutrophil-mediated clearance. Infect. Immun. 78, 2901–2909 (2010).20421378 10.1128/IAI.00188-10
86. De Gouw D Diavatopoulos DA Bootsma HJ Hermans PW Mooi FR Pertussis: a matter of immune modulation FEMS Microbiol. Rev. 2011 35 441 474 10.1111/j.1574-6976.2010.00257.x 21204863
De Gouw, D., Diavatopoulos, D. A., Bootsma, H. J., Hermans, P. W. & Mooi, F. R. Pertussis: a matter of immune modulation. FEMS Microbiol. Rev. 35, 441–474 (2011).21204863 10.1111/j.1574-6976.2010.00257.x
87. Hegerle N Guiso N Antibody-mediated inhibition of Bordetella pertussis adenylate cyclase–haemolysin-induced macrophage cytotoxicity is influenced by variations in the bacterial population Microbiology 2014 160 962 969 10.1099/mic.0.074690-0 24554758
Hegerle, N. & Guiso, N. Antibody-mediated inhibition of Bordetella pertussis adenylate cyclase–haemolysin-induced macrophage cytotoxicity is influenced by variations in the bacterial population. Microbiology 160, 962–969 (2014).24554758 10.1099/mic.0.074690-0
88. Edwards KM Adult immunization with acellular pertussis vaccine JAMA 1993 269 53 56 10.1001/jama.1993.03500010063032 8416406
Edwards, K. M. et al. Adult immunization with acellular pertussis vaccine. JAMA 269, 53–56 (1993).8416406 10.1001/jama.1993.03500010063032
89. Podda A Comparative study of a whole-cell pertussis vaccine and a recombinant acellular pertussis vaccine. The Italian Multicenter Group for the Study of Recombinant Acellular Pertussis Vaccine J. Pediatr. 1994 124 921 926 10.1016/S0022-3476(05)83181-6 8201477
Podda, A. et al. Comparative study of a whole-cell pertussis vaccine and a recombinant acellular pertussis vaccine. The Italian Multicenter Group for the Study of Recombinant Acellular Pertussis Vaccine. J. Pediatr. 124, 921–926 (1994).8201477 10.1016/S0022-3476(05)83181-6
90. Cotter PA Filamentous hemagglutinin of Bordetella bronchiseptica is required for efficient establishment of tracheal colonization Infect. Immun. 1998 66 5921 5929 10.1128/IAI.66.12.5921-5929.1998 9826374
Cotter, P. A. et al. Filamentous hemagglutinin of Bordetella bronchiseptica is required for efficient establishment of tracheal colonization. Infect. Immun. 66, 5921–5929 (1998).9826374 10.1128/IAI.66.12.5921-5929.1998
91. Leininger E Pertactin, an Arg-Gly-Asp-containing Bordetella pertussis surface protein that promotes adherence of mammalian cells Proc. Natl Acad. Sci. USA 1991 88 345 349 10.1073/pnas.88.2.345 1988935
Leininger, E. et al. Pertactin, an Arg-Gly-Asp-containing Bordetella pertussis surface protein that promotes adherence of mammalian cells. Proc. Natl Acad. Sci. USA 88, 345–349 (1991).1988935 10.1073/pnas.88.2.345
92. Scheller EV Cotter PA Bordetella filamentous hemagglutinin and fimbriae: critical adhesins with unrealized vaccine potential Pathog. Dis. 2015 73 ftv079 10.1093/femspd/ftv079 26416077
Scheller, E. V. & Cotter, P. A. Bordetella filamentous hemagglutinin and fimbriae: critical adhesins with unrealized vaccine potential. Pathog. Dis. 73, ftv079 (2015).26416077 10.1093/femspd/ftv079
93. Shahin RD Brennan MJ Li ZM Meade BD Manclark CR Characterization of the protective capacity and immunogenicity of the 69-kD outer membrane protein of Bordetella pertussis J. Exp. Med. 1990 171 63 73 10.1084/jem.171.1.63 2295882
Shahin, R. D., Brennan, M. J., Li, Z. M., Meade, B. D. & Manclark, C. R. Characterization of the protective capacity and immunogenicity of the 69-kD outer membrane protein of Bordetella pertussis. J. Exp. Med. 171, 63–73 (1990).2295882 10.1084/jem.171.1.63
94. Olin P Rasmussen F Gustafsson L Hallander HO Heijbel H Randomised controlled trial of two-component, three-component, and five-component acellular pertussis vaccines compared with whole-cell pertussis vaccine. Ad Hoc Group for the Study of Pertussis Vaccines Lancet 1997 350 1569 1577 10.1016/S0140-6736(97)06508-2 9393335
Olin, P., Rasmussen, F., Gustafsson, L., Hallander, H. O. & Heijbel, H. Randomised controlled trial of two-component, three-component, and five-component acellular pertussis vaccines compared with whole-cell pertussis vaccine. Ad Hoc Group for the Study of Pertussis Vaccines. Lancet 350, 1569–1577 (1997).9393335 10.1016/S0140-6736(97)06508-2
95. Di Tommaso A Identification of subregions of Bordetella pertussis filamentous hemagglutinin that stimulate human T-cell responses Infect. Immun. 1991 59 3313 3315 10.1128/iai.59.9.3313-3315.1991 1715327
Di Tommaso, A. et al. Identification of subregions of Bordetella pertussis filamentous hemagglutinin that stimulate human T-cell responses. Infect. Immun. 59, 3313–3315 (1991).1715327 10.1128/iai.59.9.3313-3315.1991
96. King AJ Role of the polymorphic region 1 of the Bordetella pertussis protein pertactin in immunity Microbiology 2001 147 2885 2895 10.1099/00221287-147-11-2885 11700340
King, A. J. et al. Role of the polymorphic region 1 of the Bordetella pertussis protein pertactin in immunity. Microbiology 147, 2885–2895 (2001).11700340 10.1099/00221287-147-11-2885
97. Rodríguez ME Hellwig SM Pérez Vidakovics ML Berbers GA van de Winkel JG Bordetella pertussis attachment to respiratory epithelial cells can be impaired by fimbriae-specific antibodies FEMS Immunol. Med. Microbiol. 2006 46 39 47 10.1111/j.1574-695X.2005.00001.x 16420595
Rodríguez, M. E., Hellwig, S. M., Pérez Vidakovics, M. L., Berbers, G. A. & van de Winkel, J. G. Bordetella pertussis attachment to respiratory epithelial cells can be impaired by fimbriae-specific antibodies. FEMS Immunol. Med. Microbiol. 46, 39–47 (2006).16420595 10.1111/j.1574-695X.2005.00001.x
98. Berggård K Lindahl G Dahlbäck B Blom AM Bordetella pertussis binds to human C4b-binding protein (C4BP) at a site similar to that used by the natural ligand C4b Eur. J. Immunol. 2001 31 2771 2780 10.1002/1521-4141(200109)31:9<2771::AID-IMMU2771>3.0.CO;2-0 11536176
Berggård, K., Lindahl, G., Dahlbäck, B. & Blom, A. M. Bordetella pertussis binds to human C4b-binding protein (C4BP) at a site similar to that used by the natural ligand C4b. Eur. J. Immunol. 31, 2771–2780 (2001).11536176 10.1002/1521-4141(200109)31:9<2771::AID-IMMU2771>3.0.CO;2-0
99. Charles I Expression of the Bordetella pertussis P.69 pertactin adhesin in Escherichia coli: fate of the carboxy-terminal domain Microbiology 1994 140 3301 3308 10.1099/13500872-140-12-3301 7881548
Charles, I. et al. Expression of the Bordetella pertussis P.69 pertactin adhesin in Escherichia coli: fate of the carboxy-terminal domain. Microbiology 140, 3301–3308 (1994).7881548 10.1099/13500872-140-12-3301
100. Everest P Role of the Bordetella pertussis P.69/pertactin protein and the P.69/pertactin RGD motif in the adherence to and invasion of mammalian cells Microbiology 1996 142 3261 3268 10.1099/13500872-142-11-3261 8969522
Everest, P. et al. Role of the Bordetella pertussis P.69/pertactin protein and the P.69/pertactin RGD motif in the adherence to and invasion of mammalian cells. Microbiology 142, 3261–3268 (1996).8969522 10.1099/13500872-142-11-3261
101. Storsaeter J Hallander HO Gustafsson L Olin P Levels of anti-pertussis antibodies related to protection after household exposure to Bordetella pertussis Vaccine 1998 16 1907 1916 10.1016/S0264-410X(98)00227-8 9796042
Storsaeter, J., Hallander, H. O., Gustafsson, L. & Olin, P. Levels of anti-pertussis antibodies related to protection after household exposure to Bordetella pertussis. Vaccine 16, 1907–1916 (1998).9796042 10.1016/S0264-410X(98)00227-8
102. Hijnen M Epitope structure of the Bordetella pertussis protein P.69 pertactin, a major vaccine component and protective antigen Infect. Immun. 2004 72 3716 3723 10.1128/IAI.72.7.3716-3723.2004 15213111
Hijnen, M. et al. Epitope structure of the Bordetella pertussis protein P.69 pertactin, a major vaccine component and protective antigen. Infect. Immun. 72, 3716–3723 (2004).15213111 10.1128/IAI.72.7.3716-3723.2004
103. Lesne E Acellular pertussis vaccines induce anti-pertactin bactericidal antibodies which drives the emergence of Pertactin-negative strains Front. Microbiol 2020 11 2108 10.3389/fmicb.2020.02108 32983069
Lesne, E. et al. Acellular pertussis vaccines induce anti-pertactin bactericidal antibodies which drives the emergence of Pertactin-negative strains. Front. Microbiol 11, 2108 (2020).32983069 10.3389/fmicb.2020.02108
104. Hellwig SM Rodriguez ME Berbers GA van de Winkel JG Mooi FR Crucial role of antibodies to pertactin in Bordetella pertussis immunity J. Infect. Dis. 2003 188 738 742 10.1086/377283 12934190
Hellwig, S. M., Rodriguez, M. E., Berbers, G. A., van de Winkel, J. G. & Mooi, F. R. Crucial role of antibodies to pertactin in Bordetella pertussis immunity. J. Infect. Dis. 188, 738–742 (2003).12934190 10.1086/377283
105. Weiss AA Mobberley PS Fernandez RC Mink CM Characterization of human bactericidal antibodies to Bordetella pertussis Infect. Immun. 1999 67 1424 1431 10.1128/IAI.67.3.1424-1431.1999 10024590
Weiss, A. A., Mobberley, P. S., Fernandez, R. C. & Mink, C. M. Characterization of human bactericidal antibodies to Bordetella pertussis. Infect. Immun. 67, 1424–1431 (1999).10024590 10.1128/IAI.67.3.1424-1431.1999
106. Jongerius I Schuijt TJ Mooi FR Pinelli E Complement evasion by Bordetella pertussis: implications for improving current vaccines J. Mol. Med. 2015 93 395 402 10.1007/s00109-015-1259-1 25686752
Jongerius, I., Schuijt, T. J., Mooi, F. R. & Pinelli, E. Complement evasion by Bordetella pertussis: implications for improving current vaccines. J. Mol. Med. 93, 395–402 (2015).25686752 10.1007/s00109-015-1259-1
107. Marzouqi I Richmond P Fry S Wetherall J Mukkur T Development of improved vaccines against whooping cough: current status Hum. Vaccines 2010 6 543 553 10.4161/hv.6.7.11413
Marzouqi, I., Richmond, P., Fry, S., Wetherall, J. & Mukkur, T. Development of improved vaccines against whooping cough: current status. Hum. Vaccines 6, 543–553 (2010).10.4161/hv.6.7.11413
108. Knight JB Immunogenicity and protective efficacy of a recombinant filamentous haemagglutinin from Bordetella pertussis Clin. Exp. Immunol. 2006 144 543 551 10.1111/j.1365-2249.2006.03097.x 16734625
Knight, J. B. et al. Immunogenicity and protective efficacy of a recombinant filamentous haemagglutinin from Bordetella pertussis. Clin. Exp. Immunol. 144, 543–551 (2006).16734625 10.1111/j.1365-2249.2006.03097.x
109. Relman DA Domenighini M Tuomanen E Rappuoli R Falkow S Filamentous hemagglutinin of Bordetella pertussis: nucleotide sequence and crucial role in adherence Proc. Natl Acad. Sci. USA 1989 86 2637 2641 10.1073/pnas.86.8.2637 2539596
Relman, D. A., Domenighini, M., Tuomanen, E., Rappuoli, R. & Falkow, S. Filamentous hemagglutinin of Bordetella pertussis: nucleotide sequence and crucial role in adherence. Proc. Natl Acad. Sci. USA 86, 2637–2641 (1989).2539596 10.1073/pnas.86.8.2637
110. Weingart CL Weiss AA Bordetella pertussis virulence factors affect phagocytosis by human neutrophils Infect. Immun. 2000 68 1735 1739 10.1128/IAI.68.3.1735-1739.2000 10679000
Weingart, C. L. & Weiss, A. A. Bordetella pertussis virulence factors affect phagocytosis by human neutrophils. Infect. Immun. 68, 1735–1739 (2000).10679000 10.1128/IAI.68.3.1735-1739.2000
111. Henderson MW Contribution of Bordetella filamentous hemagglutinin and adenylate cyclase toxin to suppression and evasion of interleukin-17-mediated inflammation Infect. Immun. 2012 80 2061 2075 10.1128/IAI.00148-12 22473603
Henderson, M. W. et al. Contribution of Bordetella filamentous hemagglutinin and adenylate cyclase toxin to suppression and evasion of interleukin-17-mediated inflammation. Infect. Immun. 80, 2061–2075 (2012).22473603 10.1128/IAI.00148-12
112. McGuirk P Mills KH Direct anti-inflammatory effect of a bacterial virulence factor: IL-10-dependent suppression of IL-12 production by filamentous hemagglutinin from Bordetella pertussis Eur. J. Immunol. 2000 30 415 422 10.1002/1521-4141(200002)30:2<415::AID-IMMU415>3.0.CO;2-X 10671196
McGuirk, P. & Mills, K. H. Direct anti-inflammatory effect of a bacterial virulence factor: IL-10-dependent suppression of IL-12 production by filamentous hemagglutinin from Bordetella pertussis. Eur. J. Immunol. 30, 415–422 (2000).10671196 10.1002/1521-4141(200002)30:2<415::AID-IMMU415>3.0.CO;2-X
113. Trinchieri G Interleukin-12 and the regulation of innate resistance and adaptive immunity Nat. Rev. Immunol. 2003 3 133 146 10.1038/nri1001 12563297
Trinchieri, G. Interleukin-12 and the regulation of innate resistance and adaptive immunity. Nat. Rev. Immunol. 3, 133–146 (2003).12563297 10.1038/nri1001
114. Higgs R Higgins S Ross P Mills K Immunity to the respiratory pathogen Bordetella pertussis Mucosal. Immunol. 2012 5 485 500 10.1038/mi.2012.54 22718262
Higgs, R., Higgins, S., Ross, P. & Mills, K. Immunity to the respiratory pathogen Bordetella pertussis. Mucosal. Immunol. 5, 485–500 (2012).22718262 10.1038/mi.2012.54
115. Kimura A Mountzouros KT Relman DA Falkow S Cowell JL Bordetella pertussis filamentous hemagglutinin: evaluation as a protective antigen and colonization factor in a mouse respiratory infection model Infect. Immun. 1990 58 7 16 10.1128/iai.58.1.7-16.1990 2294058
Kimura, A., Mountzouros, K. T., Relman, D. A., Falkow, S. & Cowell, J. L. Bordetella pertussis filamentous hemagglutinin: evaluation as a protective antigen and colonization factor in a mouse respiratory infection model. Infect. Immun. 58, 7–16 (1990).2294058 10.1128/iai.58.1.7-16.1990
116. Mills KH Ryan M Ryan E Mahon BP A murine model in which protection correlates with pertussis vaccine efficacy in children reveals complementary roles for humoral and cell-mediated immunity in protection against Bordetella pertussis Infect. Immun. 1998 66 594 602 10.1128/IAI.66.2.594-602.1998 9453614
Mills, K. H., Ryan, M., Ryan, E. & Mahon, B. P. A murine model in which protection correlates with pertussis vaccine efficacy in children reveals complementary roles for humoral and cell-mediated immunity in protection against Bordetella pertussis. Infect. Immun. 66, 594–602 (1998).9453614 10.1128/IAI.66.2.594-602.1998
117. Goebel EM Zhang X Harvill ET Bordetella pertussis infection or vaccination substantially protects mice against B. bronchiseptica infection PLoS One 2009 4 e6778 10.1371/journal.pone.0006778 19707559
Goebel, E. M., Zhang, X. & Harvill, E. T. Bordetella pertussis infection or vaccination substantially protects mice against B. bronchiseptica infection. PLoS One 4, e6778 (2009).19707559 10.1371/journal.pone.0006778
118. Goldberg A Fridman O Ronin I Balaban NQ Systematic identification and quantification of phase variation in commensal and pathogenic Escherichia coli Genome Med. 2014 6 112 10.1186/s13073-014-0112-4 25530806
Goldberg, A., Fridman, O., Ronin, I. & Balaban, N. Q. Systematic identification and quantification of phase variation in commensal and pathogenic Escherichia coli. Genome Med. 6, 112 (2014).25530806 10.1186/s13073-014-0112-4
119. Zeddeman A Effect of FHA and Prn on Bordetella pertussis colonization of mice is dependent on vaccine type and anatomical site Plos one 2020 15 e0237394 10.1371/journal.pone.0237394 32822419
Zeddeman, A. et al. Effect of FHA and Prn on Bordetella pertussis colonization of mice is dependent on vaccine type and anatomical site. Plos one 15, e0237394 (2020).32822419 10.1371/journal.pone.0237394
120. Carbonetti NH Highlights of the 11th International Bordetella Symposium: from basic biology to vaccine development Clin. Vaccin. Immunol. 2016 23 842 850 10.1128/CVI.00388-16
Carbonetti, N. H. et al. Highlights of the 11th International Bordetella Symposium: from basic biology to vaccine development. Clin. Vaccin. Immunol. 23, 842–850 (2016).10.1128/CVI.00388-16
121. Ciabattini A Modulation of primary immune response by different vaccine adjuvants Front. Immunol. 2016 7 427 10.3389/fimmu.2016.00427 27781036
Ciabattini, A. et al. Modulation of primary immune response by different vaccine adjuvants. Front. Immunol. 7, 427 (2016).27781036 10.3389/fimmu.2016.00427
122. Howlader DR Development of a novel S. Typhi and Paratyphi A outer membrane vesicles based bivalent vaccine against enteric fever PLoS One 2018 13 e0203631 10.1371/journal.pone.0203631 30216367
Howlader, D. R. et al. Development of a novel S. Typhi and Paratyphi A outer membrane vesicles based bivalent vaccine against enteric fever. PLoS One 13, e0203631 (2018).30216367 10.1371/journal.pone.0203631
123. Yazdankhah SP Caugant DA Neisseria meningitidis: an overview of the carriage state J. Med. Microbiol. 2004 53 821 832 10.1099/jmm.0.45529-0 15314188
Yazdankhah, S. P. & Caugant, D. A. Neisseria meningitidis: an overview of the carriage state. J. Med. Microbiol. 53, 821–832 (2004).15314188 10.1099/jmm.0.45529-0
124. Rosenstein NE The changing epidemiology of meningococcal disease in the United States, 1992–1996 J. Infect. Dis. 1999 180 1894 1901 10.1086/315158 10558946
Rosenstein, N. E. et al. The changing epidemiology of meningococcal disease in the United States, 1992–1996. J. Infect. Dis. 180, 1894–1901 (1999).10558946 10.1086/315158
125. Tettelin H Complete genome sequence of Neisseria meningitidis serogroup B strain MC58 Science 2000 287 1809 1815 10.1126/science.287.5459.1809 10710307
Tettelin, H. et al. Complete genome sequence of Neisseria meningitidis serogroup B strain MC58. Science 287, 1809–1815 (2000).10710307 10.1126/science.287.5459.1809
126. Masignani V Pizza M Moxon ER The development of a vaccine against meningococcus B using reverse vaccinology Front. Immunol. 2019 10 751 10.3389/fimmu.2019.00751 31040844
Masignani, V., Pizza, M. & Moxon, E. R. The development of a vaccine against meningococcus B using reverse vaccinology. Front. Immunol. 10, 751 (2019).31040844 10.3389/fimmu.2019.00751
127. Borrow R Neisseria meningitidis group B correlates of protection and assay standardization-international meeting report Emory University, Atlanta, Georgia, United States, 16-17 March 2005 Vaccine 2006 24 5093 5107 10.1016/j.vaccine.2006.03.091 16838413
Borrow, R. et al. Neisseria meningitidis group B correlates of protection and assay standardization-international meeting report Emory University, Atlanta, Georgia, United States, 16-17 March 2005. Vaccine 24, 5093–5107 (2006).16838413 10.1016/j.vaccine.2006.03.091
128. Giuliani MM Measuring antigen-specific bactericidal responses to a multicomponent vaccine against serogroup B meningococcus Vaccine 2010 28 5023 5030 10.1016/j.vaccine.2010.05.014 20493284
Giuliani, M. M. et al. Measuring antigen-specific bactericidal responses to a multicomponent vaccine against serogroup B meningococcus. Vaccine 28, 5023–5030 (2010).20493284 10.1016/j.vaccine.2010.05.014
129. Biolchi A 4CMenB immunization induces serum bactericidal antibodies against non-serogroup B meningococcal strains in adolescents Infect. Dis. Ther. 2021 10 307 316 10.1007/s40121-020-00370-x 33185849
Biolchi, A. et al. 4CMenB immunization induces serum bactericidal antibodies against non-serogroup B meningococcal strains in adolescents. Infect. Dis. Ther. 10, 307–316 (2021).33185849 10.1007/s40121-020-00370-x
130. Biolchi A Multicomponent meningococcal serogroup B vaccination elicits cross-reactive immunity in infants against genetically diverse serogroup C, W and Y invasive disease isolates Vaccine 2020 38 7542 7550 10.1016/j.vaccine.2020.09.050 33036804
Biolchi, A. et al. Multicomponent meningococcal serogroup B vaccination elicits cross-reactive immunity in infants against genetically diverse serogroup C, W and Y invasive disease isolates. Vaccine 38, 7542–7550 (2020).33036804 10.1016/j.vaccine.2020.09.050
131. Leduc I The serogroup B meningococcal outer membrane vesicle-based vaccine 4CMenB induces cross-species protection against Neisseria gonorrhoeae PLoS Pathog. 2020 16 e1008602 10.1371/journal.ppat.1008602 33290434
Leduc, I. et al. The serogroup B meningococcal outer membrane vesicle-based vaccine 4CMenB induces cross-species protection against Neisseria gonorrhoeae. PLoS Pathog. 16, e1008602 (2020).33290434 10.1371/journal.ppat.1008602
132. Reyes Díaz LM VA-MENGOC-BC vaccination induces serum and mucosal anti Neisseria gonorrhoeae immune responses and reduces the incidence of gonorrhea Pediatr. Infect. Dis. J. 2021 40 375 381 10.1097/INF.0000000000003047 33591079
Reyes Díaz, L. M. et al. VA-MENGOC-BC vaccination induces serum and mucosal anti Neisseria gonorrhoeae immune responses and reduces the incidence of gonorrhea. Pediatr. Infect. Dis. J. 40, 375–381 (2021).33591079 10.1097/INF.0000000000003047
133. Capecchi B Neisseria meningitidis NadA is a new invasin which promotes bacterial adhesion to and penetration into human epithelial cells Mol. Microbiol. 2005 55 687 698 10.1111/j.1365-2958.2004.04423.x 15660996
Capecchi, B. et al. Neisseria meningitidis NadA is a new invasin which promotes bacterial adhesion to and penetration into human epithelial cells. Mol. Microbiol. 55, 687–698 (2005).15660996 10.1111/j.1365-2958.2004.04423.x
134. Rodrigues CMC Genomic surveillance of 4CMenB vaccine antigenic variants among disease-causing Neisseria meningitidis isolates, United Kingdom, 2010-2016 Emerg. Infect. Dis. 2018 24 673 682 10.3201/eid2404.171480 29553330
Rodrigues, C. M. C. et al. Genomic surveillance of 4CMenB vaccine antigenic variants among disease-causing Neisseria meningitidis isolates, United Kingdom, 2010-2016. Emerg. Infect. Dis. 24, 673–682 (2018).29553330 10.3201/eid2404.171480
135. Franzoso S Human monocytes/macrophages are a target of Neisseria meningitidis Adhesin A (NadA) J. Leukoc. Biol. 2008 83 1100 1110 10.1189/jlb.1207810 18299457
Franzoso, S. et al. Human monocytes/macrophages are a target of Neisseria meningitidis Adhesin A (NadA). J. Leukoc. Biol. 83, 1100–1110 (2008).18299457 10.1189/jlb.1207810
136. Giuliani M Human protective response induced by meningococcus B vaccine is mediated by the synergy of multiple bactericidal epitopes Sci. Rep. 2018 8 3700 10.1038/s41598-018-22057-7 29487324
Giuliani, M. et al. Human protective response induced by meningococcus B vaccine is mediated by the synergy of multiple bactericidal epitopes. Sci. Rep. 8, 3700 (2018).29487324 10.1038/s41598-018-22057-7
137. Tavano R Mapping of the Neisseria meningitidis NadA cell-binding site: relevance of predicted {alpha}-helices in the NH2-terminal and dimeric coiled-coil regions J. Bacteriol. 2011 193 107 115 10.1128/JB.00430-10 20971901
Tavano, R. et al. Mapping of the Neisseria meningitidis NadA cell-binding site: relevance of predicted {alpha}-helices in the NH2-terminal and dimeric coiled-coil regions. J. Bacteriol. 193, 107–115 (2011).20971901 10.1128/JB.00430-10
138. Marr N Protective activity of the Bordetella pertussis BrkA autotransporter in the murine lung colonization model Vaccine 2008 26 4306 4311 10.1016/j.vaccine.2008.06.017 18582518
Marr, N. et al. Protective activity of the Bordetella pertussis BrkA autotransporter in the murine lung colonization model. Vaccine 26, 4306–4311 (2008).18582518 10.1016/j.vaccine.2008.06.017
139. de Gouw D Proteomics-identified Bvg-activated autotransporters protect against Bordetella pertussis in a mouse model PLoS One 2014 9 e105011 10.1371/journal.pone.0105011 25133400
de Gouw, D. et al. Proteomics-identified Bvg-activated autotransporters protect against Bordetella pertussis in a mouse model. PLoS One 9, e105011 (2014).25133400 10.1371/journal.pone.0105011
140. Fusco WG The Haemophilus ducreyi trimeric autotransporter adhesin DsrA protects against an experimental infection in the swine model of chancroid Vaccine 2014 32 3752 3758 10.1016/j.vaccine.2014.05.031 24844153
Fusco, W. G. et al. The Haemophilus ducreyi trimeric autotransporter adhesin DsrA protects against an experimental infection in the swine model of chancroid. Vaccine 32, 3752–3758 (2014).24844153 10.1016/j.vaccine.2014.05.031
141. Ysebaert C UspA2 is a cross-protective Moraxella catarrhalis vaccine antigen Vaccine 2021 39 5641 5649 10.1016/j.vaccine.2021.08.002 34446318
Ysebaert, C. et al. UspA2 is a cross-protective Moraxella catarrhalis vaccine antigen. Vaccine 39, 5641–5649 (2021).34446318 10.1016/j.vaccine.2021.08.002
142. Raghunathan D SadA, a trimeric autotransporter from Salmonella enterica serovar Typhimurium, can promote biofilm formation and provides limited protection against infection Infect. Immun. 2011 79 4342 4352 10.1128/IAI.05592-11 21859856
Raghunathan, D. et al. SadA, a trimeric autotransporter from Salmonella enterica serovar Typhimurium, can promote biofilm formation and provides limited protection against infection. Infect. Immun. 79, 4342–4352 (2011).21859856 10.1128/IAI.05592-11
143. Alamuri P Eaton KA Himpsl SD Smith SN Mobley HL Vaccination with proteus toxic agglutinin, a hemolysin-independent cytotoxin in vivo, protects against Proteus mirabilis urinary tract infection Infect. Immun. 2009 77 632 641 10.1128/IAI.01050-08 19029299
Alamuri, P., Eaton, K. A., Himpsl, S. D., Smith, S. N. & Mobley, H. L. Vaccination with proteus toxic agglutinin, a hemolysin-independent cytotoxin in vivo, protects against Proteus mirabilis urinary tract infection. Infect. Immun. 77, 632–641 (2009).19029299 10.1128/IAI.01050-08
144. León Y Intranasal immunization of mice with multiepitope chimeric vaccine candidate based on conserved autotransporters SigA, Pic and Sap, confers protection against Shigella flexneri Vaccines 2020 8 563 10.3390/vaccines8040563 33019492
León, Y. et al. Intranasal immunization of mice with multiepitope chimeric vaccine candidate based on conserved autotransporters SigA, Pic and Sap, confers protection against Shigella flexneri. Vaccines 8, 563 (2020).33019492 10.3390/vaccines8040563
145. Winter, L. E. & Barenkamp, S. J. Immunogenicity of nontypeable Haemophilus influenzae outer membrane vesicles and protective ability in the chinchilla model of otitis media. Clin. Vaccine Immunol. 24, 10.1128/cvi.00138-17 (2017).
146. Okamura M Immunization with outer membrane protein A from Salmonella enterica serovar Enteritidis induces humoral immune response but no protection against homologous challenge in chickens Poult. Sci. 2012 91 2444 2449 10.3382/ps.2012-02303 22991526
Okamura, M. et al. Immunization with outer membrane protein A from Salmonella enterica serovar Enteritidis induces humoral immune response but no protection against homologous challenge in chickens. Poult. Sci. 91, 2444–2449 (2012).22991526 10.3382/ps.2012-02303
147. Jose J Meyer TF The autodisplay story, from discovery to biotechnical and biomedical applications Microbiol Mol. Biol. Rev. 2007 71 600 619 10.1128/MMBR.00011-07 18063719
Jose, J. & Meyer, T. F. The autodisplay story, from discovery to biotechnical and biomedical applications. Microbiol Mol. Biol. Rev. 71, 600–619 (2007).18063719 10.1128/MMBR.00011-07
148. Ruiz-Pérez F Expression of the Plasmodium falciparum immunodominant epitope (NANP)(4) on the surface of Salmonella enterica using the autotransporter MisL Infect. Immun. 2002 70 3611 3620 10.1128/IAI.70.7.3611-3620.2002 12065502
Ruiz-Pérez, F. et al. Expression of the Plasmodium falciparum immunodominant epitope (NANP)(4) on the surface of Salmonella enterica using the autotransporter MisL. Infect. Immun. 70, 3611–3620 (2002).12065502 10.1128/IAI.70.7.3611-3620.2002
149. Lambert LC Pertussis vaccine trials in the 1990s J. Infect. Dis. 2014 209 S4 S9 10.1093/infdis/jit592 24626871
Lambert, L. C. Pertussis vaccine trials in the 1990s. J. Infect. Dis. 209, S4–S9 (2014).24626871 10.1093/infdis/jit592
150. Clemens J Shin S Sur D Nair GB Holmgren J New-generation vaccines against cholera Nat. Rev. Gastroenterol. Hepatol. 2011 8 701 710 10.1038/nrgastro.2011.174 22064524
Clemens, J., Shin, S., Sur, D., Nair, G. B. & Holmgren, J. New-generation vaccines against cholera. Nat. Rev. Gastroenterol. Hepatol. 8, 701–710 (2011).22064524 10.1038/nrgastro.2011.174
151. Meyer KF Effectiveness of live or killed plague vaccines in man Bull. World Health Organ 1970 42 653 666 4988692
Meyer, K. F. Effectiveness of live or killed plague vaccines in man. Bull. World Health Organ 42, 653–666 (1970).4988692
152. Fratzke AP Gregory AE van Schaik EJ Samuel JE Coxiella burnetii whole cell vaccine produces a Th1 delayed-type hypersensitivity response in a novel sensitized mouse model Front. Immunol. 2021 12 754712 10.3389/fimmu.2021.754712 34616410
Fratzke, A. P., Gregory, A. E., van Schaik, E. J. & Samuel, J. E. Coxiella burnetii whole cell vaccine produces a Th1 delayed-type hypersensitivity response in a novel sensitized mouse model. Front. Immunol. 12, 754712 (2021).34616410 10.3389/fimmu.2021.754712
153. Garmory HS Brown KA Titball RW Salmonella vaccines for use in humans: present and future perspectives FEMS Microbiol. Rev. 2002 26 339 353 12413664
Garmory, H. S., Brown, K. A. & Titball, R. W. Salmonella vaccines for use in humans: present and future perspectives. FEMS Microbiol. Rev. 26, 339–353 (2002).12413664
154. Lange C 100 years of Mycobacterium bovis bacille Calmette-Guérin Lancet Infect. Dis. 2022 22 e2 e12 10.1016/S1473-3099(21)00403-5 34506734
Lange, C. et al. 100 years of Mycobacterium bovis bacille Calmette-Guérin. Lancet Infect. Dis. 22, e2–e12 (2022).34506734 10.1016/S1473-3099(21)00403-5
155. Levine MM Duration of efficacy of Ty21a, attenuated Salmonella typhi live oral vaccine Vaccine 1999 17 S22 S27 10.1016/S0264-410X(99)00231-5 10506405
Levine, M. M. et al. Duration of efficacy of Ty21a, attenuated Salmonella typhi live oral vaccine. Vaccine 17, S22–S27 (1999).10506405 10.1016/S0264-410X(99)00231-5
156. Jia Q A Francisella tularensis live vaccine strain (LVS) mutant with a deletion in capB, encoding a putative capsular biosynthesis protein, is significantly more attenuated than LVS yet induces potent protective immunity in mice against F. tularensis challenge Infect. Immun. 2010 78 4341 4355 10.1128/IAI.00192-10 20643859
Jia, Q. et al. A Francisella tularensis live vaccine strain (LVS) mutant with a deletion in capB, encoding a putative capsular biosynthesis protein, is significantly more attenuated than LVS yet induces potent protective immunity in mice against F. tularensis challenge. Infect. Immun. 78, 4341–4355 (2010).20643859 10.1128/IAI.00192-10
157. Clark, A. & Wolfe, D. N. Current state of anthrax vaccines and key R&D gaps moving forward. Microorganisms 8, 10.3390/microorganisms8050651 (2020).
158. Mosley JF Vaxchora: the first FDA-approved cholera vaccination in the United States P t 2017 42 638 640 29018300
Mosley, J. F. et al. Vaxchora: the first FDA-approved cholera vaccination in the United States. P t 42, 638–640 (2017).29018300
159. Beran J Dražan D Enweonye I Bhusal C Toneatto D Immunogenicity and safety of investigational MenABCWY vaccine and of 4CMenB and MenACWY vaccines administered concomitantly or alone: a Phase 2 randomized study of adolescents and young adults mSphere 2021 6 e0055321 10.1128/mSphere.00553-21 34787449
Beran, J., Dražan, D., Enweonye, I., Bhusal, C. & Toneatto, D. Immunogenicity and safety of investigational MenABCWY vaccine and of 4CMenB and MenACWY vaccines administered concomitantly or alone: a Phase 2 randomized study of adolescents and young adults. mSphere 6, e0055321 (2021).34787449 10.1128/mSphere.00553-21
160. Vila-Corcoles A Ochoa-Gondar O Preventing pneumococcal disease in the elderly: recent advances in vaccines and implications for clinical practice Drugs Aging 2013 30 263 276 10.1007/s40266-013-0060-5 23420119
Vila-Corcoles, A. & Ochoa-Gondar, O. Preventing pneumococcal disease in the elderly: recent advances in vaccines and implications for clinical practice. Drugs Aging 30, 263–276 (2013).23420119 10.1007/s40266-013-0060-5
161. Kelly DF Moxon ER Pollard AJ Haemophilus influenzae type b conjugate vaccines Immunology 2004 113 163 174 10.1111/j.1365-2567.2004.01971.x 15379976
Kelly, D. F., Moxon, E. R. & Pollard, A. J. Haemophilus influenzae type b conjugate vaccines. Immunology 113, 163–174 (2004).15379976 10.1111/j.1365-2567.2004.01971.x
162. Cartee RT A phase 1 randomized safety, reactogenicity, and immunogenicity study of Typhax: A novel protein capsular matrix vaccine candidate for the prevention of typhoid fever PLoS Negl. Trop. Dis. 2020 14 e0007912 10.1371/journal.pntd.0007912 31905228
Cartee, R. T. et al. A phase 1 randomized safety, reactogenicity, and immunogenicity study of Typhax: A novel protein capsular matrix vaccine candidate for the prevention of typhoid fever. PLoS Negl. Trop. Dis. 14, e0007912 (2020).31905228 10.1371/journal.pntd.0007912
163. Klein NP Licensed pertussis vaccines in the United States. History and current state Hum. Vaccin Immunother. 2014 10 2684 2690 10.4161/hv.29576 25483496
Klein, N. P. Licensed pertussis vaccines in the United States. History and current state. Hum. Vaccin Immunother. 10, 2684–2690 (2014).25483496 10.4161/hv.29576
164. Viviani V Biolchi A Pizza M Synergistic activity of antibodies in the multicomponent 4CMenB vaccine Expert Rev. Vaccines 2022 21 645 658 10.1080/14760584.2022.2050697 35257644
Viviani, V., Biolchi, A. & Pizza, M. Synergistic activity of antibodies in the multicomponent 4CMenB vaccine. Expert Rev. Vaccines 21, 645–658 (2022).35257644 10.1080/14760584.2022.2050697
165. Wood N Immunogenicity and safety of monovalent acellular pertussis vaccine at birth: a randomized clinical trial JAMA Pediatr. 2018 172 1045 1052 10.1001/jamapediatrics.2018.2349 30208475
Wood, N. et al. Immunogenicity and safety of monovalent acellular pertussis vaccine at birth: a randomized clinical trial. JAMA Pediatr. 172, 1045–1052 (2018).30208475 10.1001/jamapediatrics.2018.2349
166. Comstedt P Schüler W Meinke A Lundberg U The novel Lyme borreliosis vaccine VLA15 shows broad protection against Borrelia species expressing six different OspA serotypes PLoS One 2017 12 e0184357 10.1371/journal.pone.0184357 28863166
Comstedt, P., Schüler, W., Meinke, A. & Lundberg, U. The novel Lyme borreliosis vaccine VLA15 shows broad protection against Borrelia species expressing six different OspA serotypes. PLoS One 12, e0184357 (2017).28863166 10.1371/journal.pone.0184357
167. Bentancor LV Camacho-Peiro A Bozkurt-Guzel C Pier GB Maira-Litrán T Identification of Ata, a multifunctional trimeric autotransporter of Acinetobacter baumannii J. Bacteriol. 2012 194 3950 3960 10.1128/JB.06769-11 22609912
Bentancor, L. V., Camacho-Peiro, A., Bozkurt-Guzel, C., Pier, G. B. & Maira-Litrán, T. Identification of Ata, a multifunctional trimeric autotransporter of Acinetobacter baumannii. J. Bacteriol. 194, 3950–3960 (2012).22609912 10.1128/JB.06769-11
168. Bentancor LV Evaluation of the trimeric autotransporter Ata as a vaccine candidate against Acinetobacter baumannii infections Infect. Immun. 2012 80 3381 3388 10.1128/IAI.06096-11 22825448
Bentancor, L. V. et al. Evaluation of the trimeric autotransporter Ata as a vaccine candidate against Acinetobacter baumannii infections. Infect. Immun. 80, 3381–3388 (2012).22825448 10.1128/IAI.06096-11
169. Xiao L Apa is a trimeric autotransporter adhesin of Actinobacillus pleuropneumoniae responsible for autoagglutination and host cell adherence J. Basic Microbiol. 2012 52 598 607 10.1002/jobm.201100365 22143982
Xiao, L. et al. Apa is a trimeric autotransporter adhesin of Actinobacillus pleuropneumoniae responsible for autoagglutination and host cell adherence. J. Basic Microbiol. 52, 598–607 (2012).22143982 10.1002/jobm.201100365
170. Hathroubi S Loera-Muro A Guerrero-Barrera AL Tremblay YDN Jacques M Actinobacillus pleuropneumoniae biofilms: role in pathogenicity and potential impact for vaccination development Anim. Health Res. Rev. 2018 19 17 30 10.1017/S146625231700010X 29110751
Hathroubi, S., Loera-Muro, A., Guerrero-Barrera, A. L., Tremblay, Y. D. N. & Jacques, M. Actinobacillus pleuropneumoniae biofilms: role in pathogenicity and potential impact for vaccination development. Anim. Health Res. Rev. 19, 17–30 (2018).29110751 10.1017/S146625231700010X
171. Siewert LK Identification of the Bartonella autotransporter CFA as a protective antigen and hypervariable target of neutralizing antibodies in mice Proc. Natl Acad. Sci. USA 2022 119 e2202059119 10.1073/pnas.2202059119 35714289
Siewert, L. K. et al. Identification of the Bartonella autotransporter CFA as a protective antigen and hypervariable target of neutralizing antibodies in mice. Proc. Natl Acad. Sci. USA 119, e2202059119 (2022).35714289 10.1073/pnas.2202059119
172. Ruiz-Ranwez V The BtaF trimeric autotransporter of Brucella suis is involved in attachment to various surfaces, resistance to serum and virulence PLoS One 2013 8 e79770 10.1371/journal.pone.0079770 24236157
Ruiz-Ranwez, V. et al. The BtaF trimeric autotransporter of Brucella suis is involved in attachment to various surfaces, resistance to serum and virulence. PLoS One 8, e79770 (2013).24236157 10.1371/journal.pone.0079770
173. Muñoz González F The BtaF adhesin is necessary for full virulence during respiratory infection by Brucella suis and is a novel immunogen for nasal vaccination against Brucella infection Front. Immunol. 2019 10 1775 10.3389/fimmu.2019.01775 31402921
Muñoz González, F. et al. The BtaF adhesin is necessary for full virulence during respiratory infection by Brucella suis and is a novel immunogen for nasal vaccination against Brucella infection. Front. Immunol. 10, 1775 (2019).31402921 10.3389/fimmu.2019.01775
174. Kiessling AR Malik A Goldman A Recent advances in the understanding of trimeric autotransporter adhesins Med. Microbiol. Immunol. 2020 209 233 242 10.1007/s00430-019-00652-3 31865405
Kiessling, A. R., Malik, A. & Goldman, A. Recent advances in the understanding of trimeric autotransporter adhesins. Med. Microbiol. Immunol. 209, 233–242 (2020).31865405 10.1007/s00430-019-00652-3
175. Lafontaine ER The autotransporter protein BatA is a protective antigen against lethal aerosol infection with Burkholderia mallei and Burkholderia pseudomallei Vaccin. X 2019 1 100002 10.1016/j.jvacx.2018.100002
Lafontaine, E. R. et al. The autotransporter protein BatA is a protective antigen against lethal aerosol infection with Burkholderia mallei and Burkholderia pseudomallei. Vaccin. X 1, 100002 (2019).10.1016/j.jvacx.2018.100002
176. Crane DD Chlamydia trachomatis polymorphic membrane protein D is a species-common pan-neutralizing antigen Proc. Natl Acad. Sci. USA 2006 103 1894 1899 10.1073/pnas.0508983103 16446444
Crane, D. D. et al. Chlamydia trachomatis polymorphic membrane protein D is a species-common pan-neutralizing antigen. Proc. Natl Acad. Sci. USA 103, 1894–1899 (2006).16446444 10.1073/pnas.0508983103
177. Swanson KA Chlamydia trachomatis polymorphic membrane protein D is an oligomeric autotransporter with a higher-order structure Infect. Immun. 2009 77 508 516 10.1128/IAI.01173-08 19001072
Swanson, K. A. et al. Chlamydia trachomatis polymorphic membrane protein D is an oligomeric autotransporter with a higher-order structure. Infect. Immun. 77, 508–516 (2009).19001072 10.1128/IAI.01173-08
178. Hu YH Zhou HZ Jin QW Zhang J The serine protease autotransporter Tsh contributes to the virulence of Edwardsiella tarda Vet. Microbiol 2016 189 68 74 10.1016/j.vetmic.2016.04.021 27259829
Hu, Y. H., Zhou, H. Z., Jin, Q. W. & Zhang, J. The serine protease autotransporter Tsh contributes to the virulence of Edwardsiella tarda. Vet. Microbiol 189, 68–74 (2016).27259829 10.1016/j.vetmic.2016.04.021
179. Ulett GC Functional analysis of antigen 43 in uropathogenic Escherichia coli reveals a role in long-term persistence in the urinary tract Infect. Immun. 2007 75 3233 3244 10.1128/IAI.01952-06 17420234
Ulett, G. C. et al. Functional analysis of antigen 43 in uropathogenic Escherichia coli reveals a role in long-term persistence in the urinary tract. Infect. Immun. 75, 3233–3244 (2007).17420234 10.1128/IAI.01952-06
180. Harris JA Directed evaluation of enterotoxigenic Escherichia coli autotransporter proteins as putative vaccine candidates PLoS Negl. Trop. Dis. 2011 5 e1428 e1428 10.1371/journal.pntd.0001428 22163060
Harris, J. A. et al. Directed evaluation of enterotoxigenic Escherichia coli autotransporter proteins as putative vaccine candidates. PLoS Negl. Trop. Dis. 5, e1428–e1428 (2011).22163060 10.1371/journal.pntd.0001428
181. Chakraborty S Human experimental challenge with enterotoxigenic Escherichia coli elicits immune responses to canonical and novel antigens relevant to vaccine development J. Infect. Dis. 2018 218 1436 1446 10.1093/infdis/jiy312 29800314
Chakraborty, S. et al. Human experimental challenge with enterotoxigenic Escherichia coli elicits immune responses to canonical and novel antigens relevant to vaccine development. J. Infect. Dis. 218, 1436–1446 (2018).29800314 10.1093/infdis/jiy312
182. Xing Y Broad protective vaccination against systemic Escherichia coli with autotransporter antigens PLoS Pathog. 2023 19 e1011082 10.1371/journal.ppat.1011082 36800400
Xing, Y. et al. Broad protective vaccination against systemic Escherichia coli with autotransporter antigens. PLoS Pathog. 19, e1011082 (2023).36800400 10.1371/journal.ppat.1011082
183. Hendrixson, D. R. & Geme, J. W. S.III. The Haemophilus influenzae Hap serine protease promotes adherence and microcolony formation, potentiated by a soluble host protein. Mol. cell 2, 841–850 (1998).
184. Cutter D Immunization with Haemophilus influenzae Hap adhesin protects against nasopharyngeal colonization in experimental mice J. Infect. Dis. 2002 186 1115 1121 10.1086/344233 12355362
Cutter, D. et al. Immunization with Haemophilus influenzae Hap adhesin protects against nasopharyngeal colonization in experimental mice. J. Infect. Dis. 186, 1115–1121 (2002).12355362 10.1086/344233
185. Olvera A Immunogenicity and protection against Haemophilus parasuis infection after vaccination with recombinant virulence associated trimeric autotransporters (VtaA) Vaccine 2011 29 2797 2802 10.1016/j.vaccine.2011.01.105 21320547
Olvera, A. et al. Immunogenicity and protection against Haemophilus parasuis infection after vaccination with recombinant virulence associated trimeric autotransporters (VtaA). Vaccine 29, 2797–2802 (2011).21320547 10.1016/j.vaccine.2011.01.105
186. Echenique-Rivera H A naturally occurring single-residue mutation in the translocator domain of Neisseria meningitidis NhhA affects trimerization, surface localization, and adhesive capabilities Infect. Immun. 2011 79 4308 4321 10.1128/IAI.00198-11 21844231
Echenique-Rivera, H. et al. A naturally occurring single-residue mutation in the translocator domain of Neisseria meningitidis NhhA affects trimerization, surface localization, and adhesive capabilities. Infect. Immun. 79, 4308–4321 (2011).21844231 10.1128/IAI.00198-11
187. Ha NY Immunization with an autotransporter protein of Orientia tsutsugamushi provides protective immunity against scrub typhus PLoS Negl. Trop. Dis. 2015 9 e0003585 10.1371/journal.pntd.0003585 25768004
Ha, N. Y. et al. Immunization with an autotransporter protein of Orientia tsutsugamushi provides protective immunity against scrub typhus. PLoS Negl. Trop. Dis. 9, e0003585 (2015).25768004 10.1371/journal.pntd.0003585
188. Bianconi, I. et al. Genome-based approach delivers vaccine candidates against Pseudomonas aeruginosa. Front. Immunol. 9, 10.3389/fimmu.2018.03021 (2019).
189. Dorsey CW Laarakker MC Humphries AD Weening EH Bäumler AJ Salmonella enterica serotype Typhimurium MisL is an intestinal colonization factor that binds fibronectin Mol. Microbiol. 2005 57 196 211 10.1111/j.1365-2958.2005.04666.x 15948960
Dorsey, C. W., Laarakker, M. C., Humphries, A. D., Weening, E. H. & Bäumler, A. J. Salmonella enterica serotype Typhimurium MisL is an intestinal colonization factor that binds fibronectin. Mol. Microbiol. 57, 196–211 (2005).15948960 10.1111/j.1365-2958.2005.04666.x
190. Paton AW Srimanote P Woodrow MC Paton JC Characterization of Saa, a novel autoagglutinating adhesin produced by locus of enterocyte effacement-negative Shiga-toxigenic Escherichia coli strains that are virulent for humans Infect. Immun. 2001 69 6999 7009 10.1128/IAI.69.11.6999-7009.2001 11598075
Paton, A. W., Srimanote, P., Woodrow, M. C. & Paton, J. C. Characterization of Saa, a novel autoagglutinating adhesin produced by locus of enterocyte effacement-negative Shiga-toxigenic Escherichia coli strains that are virulent for humans. Infect. Immun. 69, 6999–7009 (2001).11598075 10.1128/IAI.69.11.6999-7009.2001
191. Coster TS Vaccination against shigellosis with attenuated Shigella flexneri 2a strain SC602 Infect. Immun. 1999 67 3437 3443 10.1128/IAI.67.7.3437-3443.1999 10377124
Coster, T. S. et al. Vaccination against shigellosis with attenuated Shigella flexneri 2a strain SC602. Infect. Immun. 67, 3437–3443 (1999).10377124 10.1128/IAI.67.7.3437-3443.1999
192. Mantis NJ Rol N Corthésy B Secretory IgA’s complex roles in immunity and mucosal homeostasis in the gut Mucosal. Immunol. 2011 4 603 611 10.1038/mi.2011.41 21975936
Mantis, N. J., Rol, N. & Corthésy, B. Secretory IgA’s complex roles in immunity and mucosal homeostasis in the gut. Mucosal. Immunol. 4, 603–611 (2011).21975936 10.1038/mi.2011.41
193. Tsugo K Nakamura SI Yamanaka H Une Y A study on the efficacy of the recombinant Yersinia adhesin A vaccine against yersiniosis in the early phase J. Vet. Med. Sci. 2017 79 855 863 10.1292/jvms.16-0528 28320976
Tsugo, K., Nakamura, S. I., Yamanaka, H. & Une, Y. A study on the efficacy of the recombinant Yersinia adhesin A vaccine against yersiniosis in the early phase. J. Vet. Med. Sci. 79, 855–863 (2017).28320976 10.1292/jvms.16-0528
194. Mirdita M ColabFold: making protein folding accessible to all Nat. Methods 2022 19 679 682 10.1038/s41592-022-01488-1 35637307
Mirdita, M. et al. ColabFold: making protein folding accessible to all. Nat. Methods 19, 679–682 (2022).35637307 10.1038/s41592-022-01488-1
195. Hanson SE Dowdy T Larion M Doyle MT Bernstein HD The patatin-like protein PlpD forms structurally dynamic homodimers in the Pseudomonas aeruginosa outer membrane Nat. Commun. 2024 15 4389 10.1038/s41467-024-48756-6 38782915
Hanson, S. E., Dowdy, T., Larion, M., Doyle, M. T. & Bernstein, H. D. The patatin-like protein PlpD forms structurally dynamic homodimers in the Pseudomonas aeruginosa outer membrane. Nat. Commun. 15, 4389 (2024).38782915 10.1038/s41467-024-48756-6
